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Summary
The Evidence-based Toxicology Collaboration (EBTC) was established recently to translate evidence-based 
approaches from medicine and health care to toxicology in an organized and sustained effort. The EBTC 
held a workshop on “Evidence-based Toxicology for the 21st Century: Opportunities and Challenges” in 
Research Triangle Park, North Carolina, USA on January 24-25, 2012. The presentations largely reflected 
two EBTC priorities: to apply evidence-based methods to assessing the performance of emerging pathway-
based testing methods consistent with the 2007 National Research Council report on “Toxicity Testing 
in the 21st Century” as well as to adopt a governance structure and work processes to move that effort 
forward. The workshop served to clarify evidence-based approaches and to provide food for thought on 
substantive and administrative activities for the EBTC. Priority activities include conducting pilot studies 
to demonstrate the value of evidence-based approaches to toxicology, as well as conducting educational 
outreach on these approaches.
Keywords: evidence-based toxicology, evidence-based medicine, systematic review, validation, test method 
assessment
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1 http://www.ebtox.com
toolbox.1 Guiding principles of the EBTC include transparency, 
objectivity, and consistency (Hoffmann et al., in press). 
These evidence-based principles and approaches are being 
drawn and adapted from the more established field of Evidence-
based Medicine (EBM) (Hartung, 2009). EBM pioneered the 
use of systematic reviews and similar structured, transparent 
approaches to assessing evidence concerning health care in-
terventions. Innovative but sporadic attempts have been made 
1  Introduction
Formed in 2011, the Evidence-based Toxicology Collabora-
tion (EBTC) is a consortium of stakeholders from academia, 
government, and industry promoting the use of evidence-based 
approaches in toxicology. The EBTC’s goals are to strengthen 
the scientific foundation of toxicological decision making and 
to facilitate the continuous improvement of the toxicological 
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to apply these approaches in toxicology (e.g., Guzelian et al., 
2005; Navas-Acien, 2006; Griesinger et al., 2009). The EBTC 
has taken on the challenge of establishing evidence-based toxi-
cology (EBT) in a more organized and sustained effort. 
To jumpstart its efforts, the EBTC held a workshop on “Evi-
dence-based Toxicology for the 21st Century: Opportunities and 
Challenges” at the U.S. Environmental Protection Agency cam-
pus in Research triangle Park, North Carolina, USA on January 
24-25, 2012. The backbone of the workshop was a set of four 
sessions, each kicked off by one or more formal presentations, 
followed by invited discussants, and then general discussions 
(Tab. 1). The full workshop agenda, which included introduc-
tory and concluding presentations, is available online.2
The program reflected a number of the EBTC’s priorities. 
First, the EBTC is seeking to apply evidence-based methods to 
assessing the performance of emerging pathway-based methods 
consistent with the National Research Council (NRC) report on 
“Toxicity Testing in the 21st Century” (NRC, 2007). In keeping 
with this priority, workshop Session 1 featured a presentation by 
Richard Judson on the validation of high-throughput pathway-
based assays (Judson et al., 2013) and Session 3 featured a pres-
entation by Suzanne Fitzpatrick on a potential role for EBT in 
21st century validation strategies (see Section 5.1). Similarly, 
two of the three presentations in Session 2 addressed fundamen-
tal questions relevant to establishing the scientific basis of path-
way-based assays – one by Daland Juberg on the challenge of 
distinguishing adverse responses in these assays from those that 
are adaptive or compensatory (see Keller et al., 2012), and one 
by Patricia Harlow on the process of confirming that biomark-
ers used in these and related assays truly reflect the biology of 
interest (see Section 4.1).
A second EBTC priority is establishing an administrative 
structure and operational procedures that not only facilitate the 
work of the EBTC but also reflect core EBM/EBT principles, 
including transparency, continuous improvement, and volunteer 
inclusion. This priority was addressed in a presentation by John 
Fowle in workshop Session 4 (see Section 6.1).
And finally, Ellen Silbergeld, who gave a presentation in Ses-
sion 2, provided helpful background information on evidence-
based approaches and early attempts to apply them to EBT (Sil-
bergeld and Scherer, 2013).
Given the novelty of evidence-based approaches in toxicology, 
the workshop program included ample time for both commen-
taries by invited discussants and discussion among workshop 
participants. To facilitate this commentary, the primary speakers 
were asked to circulate their presentations – in the form of white 
papers or Powerpoint slides – in advance to the invited discus-
sants. The discussants were free to react to the presentations in 
their sessions or to discuss related issues. 
the papers associated with the formal presentations in each 
of the four workshop sessions either appear elsewhere in this 
issue of ALTEX (Judson, 2013; Silbergeld and Scherer, 2013) or 
are summarized below, except the one associated with Daland 
Juberg’s presentation, which was already in press at the time of 
the EBTC workshop (Keller et al., 2012). A science writer was 
contracted to take the lead in summarizing the invited commen-
taries and open discussions for the proceedings, except where 
noted otherwise below. The invited discussants and the com-
mentators were given an opportunity to review and offer edits 
to the draft summary prior to its completion. 
2 http://www.ebtox.com
Tab. 1: The four core sessions of the Evidence-based Toxicology Collaboration (EBTC) workshop on  
Evidence-based Toxicology for the 21st Century: Opportunities and Challenges
Held January 24-25, 2012 in Research Triangle Park, North Carolina, USA*
Session Topics 1. Pathway Validation 2. Case Studies 3. EBTC Priorities 4. EBTC Governance
Presenters Richard Judson Ellen Silbergeld Suzanne Fitzpatrick John Fowle 
 (US EPA) (Johns Hopkins University) (US FDA) (US EPA, retired)
  Daland Juberg  
  (Dow Agrosciences)
  Patricia Harlow  
  (US FDA)
Invited Discussants Douglas Wolf Robert Chapin Tim Pastoor Roberta Scherer  
	 (US	EPA)	 (Pfizer)	 (Syngenta)	 (Johns	Hopkins)
 Ed Carney Kim Boekelheide Olga Naidenko Rashid Shaikh  
 (Dow Chemical) (Brown University) (Environmental Working (Health Effects Institute) 
   Group) 
 Grace Patlewicz Richard Judson Michael Holsapple Dennis Devlin  
 (DuPont) (US EPA) (Battelle) (ExxonMobil)
    Andrew Rowan  
    (Humane Society  
    International)
* The full workshop agenda, which included introductory and concluding presentations, is available online at http://www.ebtox.com.
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US and Europe. The EBTC traces its beginnings to a 2010 
workshop in the United States on “21st Century Validation for 
21st Century tools,” which featured a session on the potential 
for evidence-based approaches to assess the performance of a 
new generation of non-animal test methods (Hartung, 2010). 
the eBtC formed in the ensuing months and held a kick-off 
meeting on eBt as a satellite to the 2011 Society of toxicology 
annual conference in the US. The meeting familiarized the pri-
marily US-based audience with the basic concepts and promise 
of EBT (Zurlo, 2011). It was well attended and generated en-
thusiasm for pressing forward to develop EBT approaches. The 
tasks to be tackled included identifying priorities, establishing 
work groups, developing a governance structure and work proc-
esses as appropriate, and engaging interested stakeholders in the 
process. It was decided to jumpstart these efforts by holding an 
open workshop.
the March 2011 kick-off event was replicated at the 2012 eu-
roTox conference for the European branch of the EBTC (Hoff-
mann, 2012). 
Given its genesis at a workshop on validation of new meth-
ods, the eBtC has retained a keen interest in applying evidence-
based approaches to assessing test method performance. 
the launching of the eBtC is timely, as the toxicology litera-
ture increasingly invokes eB-related themes or practices such 
as transparency in decision-making (Schreider et al., 2010), 
systematic and transparent reviews of evidence (Sutton et al., 
2011), synthesis of types of evidence to establish causal infer-
ence (Adami et al., 2011), and assessment of bias/credibility 
(Conrad and Becker, 2010). We also see practical examples of 
the application of evidence-based methodology or terminology 
(Woodruff et al., 2011; Abhyankar et al., 2011; Maull et al., 
2012).
Evidence-based approaches provide a means of critically ap-
praising evidence in a manner that is transparent, objective, and 
consistent. By contrast, standard toxicological practice still in-
cludes narrative (and thus subjective) reviews, non-transparent 
weight-of-evidence approaches, inconsistent decision-making 
procedures regarding the assessment of the hazards and risk 
of individual compounds, and reliance on aged toxicological 
methods of unclear performance. These practices compromise 
decision making and retard innovation in testing methods. In-
novation is hampered further by prevailing frameworks for as-
sessing toxicological test methods (i.e., validation), which are 
time-consuming, expensive, and intrinsically biased towards 
traditional methods. 
To remedy these limitations, approaches have been proposed 
that build on EBM methodologies (such as systematic reviews) 
and practices (such as those established by the Cochrane Col-
laboration5). Unfortunately, attempts at implementing these ap-
proaches in toxicology remain uncommon and fragmentary. 
the North Carolina workshop provided a forum for eBtC 
members and interested stakeholders to offer and discuss toxi-
cological and organizational priorities for the collaboration.
2  Background information on Evidence-based 
Medicine and Evidence-based Toxicology
Evidence-based approaches have strengthened the scientific 
foundation of decision making in clinical medicine and health 
care by providing a structured framework for assessing the evi-
dence bearing on healthcare questions. Moreover, such critical 
appraisals of past studies inevitably encourage improvements in 
the prospective design and reporting of new studies. Evidence-
based tools are expected to have a similar impact on toxicology 
when appropriately translated from the medical context.
the primary tool of eBM is the systematic review, which in-
cludes a variety of steps: framing the question to be addressed 
and deciding on how relevant studies will be identified and 
retrieved, which studies will be excluded from the analysis, 
how the included studies will be appraised for their risk of bias/
quality, and how the data will be synthesized across studies 
(e.g., meta-analysis). Such reviews also reflect EBM’s hall-
mark tenets of transparency, objectivity, and consistency to the 
maximum extent possible. In addition, systematic reviews 
provide a convenient way for interested stakeholders to gain 
a condensed snapshot of the key literature and findings on a 
given subject.
Although eBM has earlier historical antecedents, its rise as 
a distinct discipline is usually credited to the work and advo-
cacy of Scottish epidemiologist Archie Cochrane (e.g., May-
er, 2004). The term “evidence-based” was coined by Gordon 
Guyatt in 1990, and “evidence-based medicine” first appears 
in the medical literature in 1992 (Guyatt et al., 1992). The Co-
chrane Collaboration, named in honor of Archie Cochrane, was 
launched at Oxford University in 1993 to promote evidence-
based reviews of the clinical medicine literature. By 2011, the 
Cochrane Collaboration had more than 28,000 active contribu-
tors in more than 100 countries, and the Cochrane Library3 con-
tained more than 4,400 systematic reviews (see commentary by 
Scherer in Section 6.2).
The translation of evidence-based approaches from medicine 
to toxicology is already underway, at least at the conceptual 
level, but this process is only a decade old and still in the form-
ative stage. Guzelian et al. (2005) coined the phrase “evidence-
based toxicology” (EBT) and noted its promise in assessing the 
evidence that specific chemicals cause specific health effects in 
humans. Around the same time, Hoffmann and Hartung (2005) 
noted the potential value in translating evidence-based assess-
ments of diagnostic measures in medicine to assessments of 
test methods in toxicology. Hartung and Hoffmann went on to 
further elaborate the conceptual underpinnings of EBT (Hoff-
mann and Hartung, 2006; Hartung, 2009) and coordinate the 
first international conference on EBT, held in Italy in 2007 
(Griesinger et al., 2009).
Hartung later founded the EBTC – the collaboration devoted 
to advancing EBT – with several partners.4 For practical pur-
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would be useful for predicting wildlife effects, as well as the 
technical concerns that may prove important, such as how to run 
assays for cold-blooded animals, he said. 
3.2  Invited discussant Ed Carney 
ed Carney of the Dow Chemical Company was the second in-
vited discussant. He noted that some whole-animal-based as-
says for developmental and reproductive toxicity have been 
able to identify unique effects that scientists otherwise would 
not have been able to predict. In his experience, however, the 
observed effects are mostly seen only at doses that are orders of 
magnitude higher than human exposure. 
Carney said that his own declining satisfaction with the utility 
of whole-animal tests reinforces the need for a new paradigm. 
He agreed with Wolf that a prerequisite for moving forward with 
high-throughput pathway-based assays is a process whereby all 
stakeholders gain confidence in their utility. 
Carney argued that the best place to begin using high-through-
put cell-based assays is with prioritization. There is a strong 
need for increasing the capacity of doing such baseline assess-
ments, given that there is only a limited capacity for conducting 
animal-based tests. The throughput (high) and the cost (low) of 
the pathway-based assays match the need, he said. Currently, 
prioritization is needed mainly for chemicals with very little 
data, so in effect, the bar is lower than for other applications 
such as risk assessment. 
However, Carney cautioned that fitness for prioritization does 
not guarantee fitness for risk assessment. We need operating dis-
cipline to prevent inappropriate uses, he said. For example, the 
post-implantation rat whole-embryo culture (WEC) and the Em-
bryonic Stem Cell Test (EST) are appropriate for embryo toxicity 
screening; he noted that the european Centre for the Validation 
of Alternative Methods (ECVAM) is careful to use qualifying 
language stressing that these cell-based assays are not valid as 
replacements for in vivo developmental toxicity tests. 
A strong causal connection between altered biology in the 
high-throughput assays and adverse apical outcomes is needed 
to justify use in decision-making, he said. The strength of this 
connection currently varies with different types of cell-based 
assays. He offered the examples of the estrogen receptor and 
androgen receptor as ones in which both the pathways and the 
requirements for adverse outcomes are relatively well under-
stood. The association is weaker for other assay endpoints. Case 
examples are needed to establish proof of principles, he said.
A practical challenge is to choose which assays to enter into 
validation exercises, he noted. Some are ready; some are not. 
Establishing an assay’s suitability for a narrow intended pur-
pose should be relatively straightforward. A harder challenge 
comes when moving from single assays to groups of assays that 
query pathways. Validation then should shift to evaluating the 
predictive value of groups of complementary assays, Carney 
asserted.
Carney stressed that it is also important to consider the nature 
of industrial chemicals. They often have very general functional 
properties that drive their use in commerce, such as surfactants 
in cleaning agents. This raises the possibility of confounding 
results, such as when a tested chemical denatures a target pro-
3  Workshop Session 1:  
The validation of high-throughput  
pathway-based assays
This session featured a presentation by Richard Judson  
(see Judson et al., 2013). 
3.1  Invited discussant Douglas Wolf 
The first discussant was Douglas Wolf, who at the time was 
the acting director of the Environmental Protection Agency’s 
(EPA’s) Exposure Assessment Coordination Policy division in 
the Office of Science Coordination and Policy, which, in turn, is 
in the Office of Chemical Safety and Pollution Prevention. This 
division is responsible for the Endocrine Disruptor Screening 
Program (EDSP). Wolf has since become the Assistant Labora-
tory Director of EPA’s National Health and Environmental Ef-
fects Research Laboratory, which is part of the agency’s Office 
of Research and Development.
Wolf raised several points. He noted that the 1996 Food Qual-
ity Protection Act has language stipulating that ePA must use 
validated methods to determine if a chemical has the ability to 
disrupt the endocrine system. In the plan published on the EDSP 
website, EPA is proposing a phased process. Initially, the agen-
cy is using high-throughput methods to help inform its proc-
ess of prioritizing chemicals for more detailed testing. The re-
sults of the high-throughput assays, together with data from the 
agency’s exposure evaluation and other available information, 
are helping the agency to determine which chemicals should be 
tested initially.
Over time, EPA will begin to replace current methods with 
high-throughput assays, Wolf predicted. This will happen after 
the agency evaluates the high-throughput methods, is able to 
show that they do indeed predict the potential for disrupting the 
endocrine system, and can either validate them or build confi-
dence in their use. In the short term, Wolf said it will be easy to 
replace current in vitro methods with higher throughput assays. 
In the longer term, Wolf predicted that the high-throughput as-
says will replace whole animal methods. 
Wolf suggested that the eBtC consider focusing its valida-
tion-oriented efforts on the high-throughput assays that were 
purposely designed for robotic systems, because we do not have 
experience validating these higher throughput systems. Efforts 
to determine how to validate them would constitute the best use 
of the EBTC’s time and resources.
Wolf said that the EPA’s goal is to provide a level of con-
fidence in the agency’s testing methods that will assure their 
validity to all stakeholders. 
Finally, Wolf pointed out that it is important to have cell-based 
assays to evaluate a chemical’s impact not only on human health 
but also on the environment, such as effects on wildlife. Most 
of the focus to date has been on systems based on human cells, 
cell lines, and mechanistic considerations, mainly because the 
pharmaceutical industry has taken the lead in developing high-
throughput assay systems. “We at the EPA are equally concerned 
with environment and wildlife as we are with human health, so 
all of those are going to be necessary.” The research community 
should be thinking about what kind of high-throughput assays 
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action (MOA); and 3) Utilization, a contextual and weight-of-
evidence analysis of a specific use of quantitative assay results 
based on all available evidence. 
With respect to analytical validation, one particularly difficult 
issue noted by Judson et al. is how to validate proprietary assays 
or those that require extensive robotics. A pragmatic approach 
for this validation could be to focus on the core basis of the 
assay and conduct either a non-proprietary assay that is comple-
mentary to the proprietary assay or to conduct one or more of 
the high-throughput assays in a low throughput mode. Neither 
proprietary nor throughput considerations should be used as 
impediments to robust scientific evaluation. Heuristic methods 
will also be important, as will consideration of the combined 
assay results – chemicals with established activities can serve as 
performance standards, and lack of consistency between assay 
results for these chemicals should be a red flag. Cross-laborato-
ry testing may also be addressed by performance standards. This 
is a core element of validation that should not be avoided due to 
practical difficulties. 
Qualification addresses how well the assay results reflect key 
events within the mode of action. Qualification will necessarily 
need to consider differences in potency and efficacy. It will be 
particularly challenging to establish the links between the assay 
results, the MOA, dose responses, and adverse effects. It is vital 
to understand how results of high-throughput assays relate to 
biological response pathways (Bhattacharya et al., 2011; Seed et 
al., 2005), especially how the quantitative result from an assay 
relates to the transition from an adaptive to an adverse response. 
With current understanding, it will be challenging to distinguish 
results that represent transient and homeostatic responses from 
results that reflect adaptive responses (that may be reversible) 
from results that are sufficient to cause an adverse outcome. 
Utilization raises the question of what level of scientific con-
fidence is needed for different purposes, whether they be screen-
ing, prioritization, hazard identification, or hazard prediction. 
Clearly, any evaluation should have the end application in mind 
(Judson et al.’s “use case”), rather than conducting a “valida-
tion” in vacuo. For example, applying high-throughput meth-
ods for priority setting would tolerate greater uncertainty than 
the same methods being applied to trigger a risk management 
regulatory decision. EBT, Bayesian approaches, or other meth-
ods may prove useful in integrating many sources of informa-
tion to arrive at a quantitative weight-of evidence-assessment. 
Furthermore, dosimetry and exposure are key in providing the 
appropriate context of how a given test concentration in a high-
throughput test system relates to a real life exposure. Use of 
high-throughput assay results in lieu of traditional toxicity tests 
to support hazard identification or hazard prediction is perhaps 
the most difficult stage to address in terms of establishing what 
level of correspondence between assay results and key events is 
really needed. 
Twenty-first century toxicology presents an exciting era for 
toxicologists, risk assessors, and researchers. Programs such as 
the U.S. EPA’s ToxCast™ exemplify how new technologies can 
be exploited to address the challenges of risk assessment. The 
challenge remaining will be validation/evaluation and gaining 
an understanding of the strengths and limitations of these types 
tein. Carney sees value in prioritizing chemicals into two broad 
categories – those exhibiting non-specific interactions, such as 
membrane alteration, and those known to have specific interac-
tions, such as effects mediated by receptors. 
3.3  Invited discussant Grace Patlewicz  
(with Richard Becker and Ted Simon)
The third respondent to the Judson presentation was Grace Pa-
tlewicz of the DuPont Haskell Global Centers for Health and 
Environmental Sciences. She opted to submit a written text for 
the proceedings in lieu of having her oral remarks summarized 
by the science writer. The text (comprising the balance of Sec-
tion 3.3.) provides recommendations focused on the paper pre-
pared by Judson et al. (2013) and is a summary of a longer doc-
ument, “ACC Perspectives on Validation of High-Throughput 
Assays Supporting 21st Century toxicity evaluation,” prepared 
by the American Chemistry Council (ACC) Computational Pro-
filing Workgroup, which she co-chairs with Richard Becker of 
the American Chemistry Council. 
Everyone recognizes that the means by which data are gener-
ated and translated into information for the purposes of chemical 
regulation and risk assessment is undergoing a massive trans-
formation. There are many drivers for this shift, including ani-
mal welfare considerations, advances in scientific techniques to 
rapidly screen substances for biological activities, and the large 
number of substances that exist in commerce for which toxic-
ity information can vary to a considerable degree. Advances in 
high-throughput technologies, including in vitro cell-based as-
says and toxicogenomics, show considerable promise in chang-
ing the manner in which toxicity testing is performed in the fu-
ture. However, the framework and context in which these types 
of data are evaluated and interpreted for regulatory decisions 
also will need to transform. The current validation process to 
develop scientific confidence in new methods to predict toxicity, 
as described by bodies such as ECVAM, the Interagency Coordi-
nating Committee on the Validation of Alternative Methods (IC-
CVAM), and the Organisation for Economic Cooperation and 
Development (OECD), also will need to adapt to encompass the 
scenario of batteries of in vitro assays being used to evaluate a 
given regulatory endpoint, rather than the current framework of 
a single assay replacing a single in vivo test protocol.
To develop scientific confidence in high-throughput assays, 
the approach described in the Institute of Medicine’s (IOM’s) 
Evaluation of Biomarkers and Surrogate Endpoints in Chronic 
Disease – namely analytic validation, qualification, and utili-
zation – warrants consideration. Analytical validation entails 
analyses of available evidence on the analytical performance 
of an assay. Qualification requires the assessment of available 
evidence on associations between the measured biomarker 
response and adverse effects. Utilization requires contextual 
analysis based on the specific use proposed and the applicabil-
ity of available evidence to this use. For high-throughput as-
says such as those in the ToxCast™ program, these steps could 
be adapted as: 1) Analytical validation, a consideration of the 
performance of an assay or suite of assays; 2) Qualification, 
an assessment of the association of the assay with a molecular 
initiating event, key event, or biomarker within the mode of 
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Mel Andersen of the Hamner Institutes for Health Sciences 
said that the most important information is what are we doing 
and why are we doing it – in other words, in how a problem 
is defined. He asked Judson if all of the assays being used to 
identify modes of action were really required to effectively 
identify them.
Judson replied that for any given context, there is a “sweet 
spot” – not too many assays and not too few. He also noted the 
importance of assessing a test’s fitness for purpose in terms of 
balancing its sensitivity and specificity to meet the test objec-
tive. Screening tests should be relatively sensitive and specific, 
although he acknowledged that it is hard to have both; cost is al-
so a factor. In any case, the purpose is not to say that a chemical 
is likely to be, say, positive in a guideline assay, he stressed.
Carl Westmoreland of Unilever, chair of workshop Session 
1 and a member of the EBTC’s European Steering Committee, 
commented that transparency was an issue that cropped up more 
than once in the discussion. Ellen Silbergeld of Johns Hopkins 
University explained that transparency has acquired a particu-
lar meaning from its association with the Cochrane Collabora-
tion for evidence-based medicine and health care (EBM/HC). 
That definition is incompatible with the idea that information 
can be shared on a “need-to-know” basis, she said. As defined 
by Cochrane, transparency is an absolute condition, Silbergeld 
stressed. Because the concept of transparency is fundamental 
to EBM, Silbergeld contended that it must also be a key tenet 
of EBT. 
Wolf responded that an evidence-based assessment of test 
method performance requires access to sufficient information 
to make a determination about the relevance, reliability, and fit-
ness for purpose of a given assay or set of assays that are being 
incorporated into a test method. This begs the question of how 
one determines that the amount of information is sufficient to 
make a scientifically defensible determination that a given test 
method is validated or validate-able; the answer may need to be 
determined on a case-by-case basis. 
Roberta Scherrer of the Cochrane Center at Johns Hopkins 
University pointed out that her center’s focus on transparency is 
driven by the goal of ensuring that all systematic review findings 
can be replicated. The organization has a publicly available pro-
tocol for how to synthesize evidence to ensure transparency. 
Patlewicz suggested that the approach the OECD is using 
for characterizing QSAR methods could be considered a useful 
framework for considering the level of information required to 
establish a given assay’s suitability for purpose. She lauded the 
framework for its discussion of measures of robustness and how 
it defined its domain of applicability. 
Maurice Whelan of the european Commission noted that 
ECVAM came up with the concept of performance-based test 
guidelines to help ensure that the agency was not “embarking 
on an endless series of tests.” The guidelines come into play in 
instances where two tests have essentially similar components 
that are intended to determine the same biological outcome. 
Once performance methods have been defined to establish re-
producibility, capacity, and accuracy, they can be applied to all 
of the methods aimed at that outcome. Performance standards 
also can be used to help guide test developers on how to imple-
of technologies for specific uses. Scientific consensus among 
regulators, regulated entities, and stakeholders will be needed in 
order to engender confidence in the use of high-throughput pre-
diction models and results for decision-making. Consensus may 
be achieved by application of a scientifically sound validation 
framework coupled with transparency (data and algorithms) 
and responsible communication. Appropriate peer review, com-
munication, and outreach are of paramount importance to the 
successful implementation, acceptance, and use of these new 
technologies by all stakeholders.
3.4  Open discussion 
After the floor was opened for questions, John Fowle, a member 
of the US eBtC Steering Committee, asked if there was a way 
to inspire companies like Dow or DuPont to share their in vitro 
and in vivo discovery data on adverse outcomes to help improve 
Quantitative Structure Activity Relationship (QSAR) models. 
Carney responded that his company (Dow) was exploring new 
approaches to bringing novel chemicals to market and integrating 
QSAR data. “We are quite interested in working with government 
agencies, particularly ePA, to look at different ways of getting 
new products approved,” he said. He said that Dow is currently 
involved in a project associated with greener and less hazardous 
substitutes, which uses some newer tools, such as in vitro assays 
and zebrafish embryos, as well as computerized structure activity 
relationship (SAR) analyses of structurally similar analogs for 
which existing data might already be available. 
Carney said that this project might eventually become a pro-
totype for a different approach to producing the Pre-Manufac-
ture Notifications that companies must submit to EPA to comply 
with the Toxic Substances Control Act. In place of guideline 
data for, say, fish acute toxicity, it might be possible to substitute 
a zebrafish embryo screen and SAR analysis, he suggested. 
Wolf sketched an interactive approach to testing that could 
inspire chemical and pharmaceutical companies to share their 
discovery data. He drew an analogy to companies developing 
open-source software applications. Many such applications are 
available that people can download for free; users can offer sug-
gestions for improvements. The software’s originator then can 
capitalize on the suggestions to make a profitable product. He 
argued that this kind of interactive approach would help amass 
important data for improving QSAR models. 
Errol Zeiger, an independent consultant, argued that data 
used to make decisions about the tests or test programs should 
be available to other people in case they want to do their own 
analyses. He added that high-throughput assays will be a suc-
cess or failure based on the individual tests used as screening 
tools, where the false-negative rate plays a crucial role, but can 
rarely be assessed.
Judson pointed out that every false-positive screening test re-
sult can force a chemical company to spend half a million dol-
lars to conduct a full battery of tests to prove that its chemical is 
actually not problematic. 
thomas Hartung of Johns Hopkins University commented 
that EBT is a new toolbox that needs to be evaluated. The beauty 
of the evidence-based approach is to transparently define a proc-
ess before you do it, thereby increasing objectivity, he stressed.
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high-throughput tests in terms of their predictive capacity. He 
asked about how the tools of EBT might be used to facilitate 
the process of determining what types of references toxicolo-
gists should strive for – and how to select chemicals to use as 
references.
Some of the questions that people have posed may be ones 
that EBT is not designed to answer, Silbergeld said. She likened 
EBM to a court of law. EBM does not determine who is guilty 
and innocent. It provides the rules of process, such as which in-
formation is admitted into the discussion and to the judgment 
process. EBT, “if it is following that same path, will do the same. 
It provides a set of methods that allow you to reduce bias in terms 
of scanning the fact landscape and presenting the information in 
a fully transparent method so everybody can replicate the proc-
ess – not the experiments – by which you identified the outcome 
by passing it through evaluatory filters. It is not going to say that 
this is more relevant than that. It will say that this is less biased 
information that can be utilized in reaching your judgment.” 
Hartung explained how EBT might aid in solving the problem 
Whelan posed about compiling a list of reference compounds. 
An evidence-based approach would be to define the process of 
compiling a list of reference compounds, to define the substanc-
es to be considered, the criteria to be applied. Before being ex-
ecuted, the process would be peer-reviewed. All the stakehold-
ers should agree that this is a fair way to identify the substances. 
This is a way of describing a process that can be reconstructed, 
which makes sense to somebody on the outside, and which does 
not require the involvement of a “pope.” 
Becker pointed out that one of the areas that are going to be 
most challenging is prediction modeling. He said that he could 
readily see how one could construct a prediction model using 
the EBT approach. To create a model, you would take the el-
ements of the assays, an element of exposure and concentra-
tion, and other relevant data and knowledge of the substances. 
Then evidence-based approaches could be used for assessing 
the quality and reliability of the data, and then they could be 
plugged into the model. “That, to me, is the process we should 
focus in on as a good case study to begin the discussion of the 
application of [EBT],” he said, concluding the session.
4  Workshop Session 2:  
Case studies 
This session featured presentations by Ellen Silbergeld (see 
Silbergeld and Scherer, 2013), Daland Juberg (see Keller et al., 
2012), and Patricia Harlow (see Section 4.1).
4.1  Biomarker Qualification at the US FDA Center 
for Drug Evaluation and Research6 
Patricia Harlow of the U.S. Food and Drug Administration’s 
(FDA’s) Center for Drug Evaluation and Research (CDER) 
gave an overview of the process that her center uses to qualify 
biomarkers, which they define as objectively measured charac-
teristics that are an indicator of biologic processes (normal or 
ment different versions of essentially the same assay on differ-
ent platforms, Whelan said. 
Performance standards may prove very helpful in the early 
stages of implementing high-throughput testing methods, Wolf 
commented. They hold promise for targeting peer-review to 
whatever a given assay is intended to accomplish, as well as what 
a validation process is intended to achieve. Because the assays 
are being used as part of a constellation meant to help provide 
decision support, they will continually evolve and be replaced. 
Performance standards could avoid the need to re-validate every 
time a method or assay is replaced by an improved version. Such 
an approach also would allow for transparency, he said.
Session chair James Freeman of ExxonMobil characterized 
what we’re talking about with EBT as a shift from validation to 
“fit-for-purpose.” We’re all steeped in the validation model, but 
maybe there is a way to get out of the validation box and move 
to fit-for-purpose, he said.
Carl Westmoreland noted the difficulty in judging when an 
assay has relevance for a toxicity endpoint or pathway of inter-
est. The issue is tied up with the relevance of the test itself, the 
cell line you are looking at, and the concentrations that you are 
testing. He invited participants to weigh in on how relevance 
could be judged in such cases.
Judson responded that relevance is where test assays will pass 
or fail. Today we can run a set of assays with a set of chemicals 
for which we have in vivo data, and we can find correlations. 
The biology makes sense. The difficulty is to step beyond that 
to suggest that correlation is causation. It is hard to support a 
claim that the output from many of the new technologies with 
different cell types, such as pathway modeling, virtual tissue 
modeling, orthogonal assays, and sandwich assays, really is tell-
ing you something definitive about what is going to happen in 
the animal, he said. 
Traditionally, toxicologists are trained to think of “relevance” 
mainly in terms of the ability to predict a type of gold standard, 
Hartung said. Such a gold standard does not always exist. How-
ever, a crucial part of validating a given test is assessing its sci-
entific basis. It is a type of relevance that the current validation 
paradigm does not exploit, yet it is exactly the kind of relevance 
needed to establish novel assays. We need to model pathways 
that are shown scientifically to be relevant for a hazard we want 
to study, he said. 
This is where the objective and transparent assessments possi-
ble with EBT can come into play, Hartung continued. When we 
can show that a scientifically sound pathway has been demon-
strated, then we have the criteria we need to justify the use of an 
assay or group of assays. This is the beauty of a different type of 
system. We should think not about being empiric by reproduc-
ing data from another type of test system, but by being scientific 
by demonstrating that we reflect the science as we know it with 
the tools of science and by the scientific method, he said.
Whelan pointed out that the process everyone struggles with 
is chemical selection. Because there are so many competing cri-
teria for selecting reference chemicals, he argued for the value 
of having many sets of reference chemicals to use to challenge 
6 This section is based on a paper prepared for the proceedings by Patricia Harlow.
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For instance, a safety biomarker whose proposed context of use 
includes multiple test animal species used for toxicology studies 
could not be qualified with data obtained only in rats. Further-
more, the evidentiary standards for biomarkers with a clinical 
context are expected to be different from those biomarkers with 
a nonclinical context of use.
Evaluation of biomarker qualification submissions involves 
CDER personnel who are common to all submissions, as well 
as personnel who are specific to that particular submission. The 
process of qualification within CDER consists of two phases: 
a consultation and advice phase and a review phase. The end 
result is that the biomarker is either qualified or not qualified in 
the stated context of use, and the review is considered complete. 
The qualification letter is posted on the CDER website.7 Fur-
ther description of the qualification process is provided at the 
CDER website and in the paper by Woodcock et al. (2011). The 
biomarker qualification program is designed to support devel-
opment of DDTs but, at the same time, to minimize burdens on 
CDER product review divisions, whose primary responsibility 
is the evaluation of data supporting applications for drug devel-
opment and drug marketing. 
Currently, eight urinary biomarkers for nephrotoxicity in rats 
have been qualified by the US FDA, as well as by the European 
Medicines Agency. The submissions for these nephrotoxicity 
biomarkers contained study reports for rat toxicology studies 
that were primarily dose-response studies for multiple nephro-
toxicants, as well as some non-nephrotoxicants. Using pooled 
data, the diagnostic performance of these biomarkers was evalu-
ated in comparison with currently used nephrotoxicity markers 
(blood urea nitrogen [BUN] and serum creatinine) using receiv-
er operating characteristic curves. The reference standard was 
histopathology of the kidney. The data indicated that these uri-
nary biomarkers could either outperform or add value to BUN 
and serum creatinine in detecting certain drug-induced kidney 
lesions (Dieterle et al., 2010a; Harpur et al., 2011; Hoffmann et 
al., 2010; Ozer et al., 2010; Vaidya et al., 2010; Yu et al., 2010). 
Some evidence supports the utility of these qualified biomarkers 
to detect injury in specific nephron segments in the rat. Changes 
in urinary kidney injury molecule-1 (KIM-1), clusterin, albu-
min, trefoil factor-3 (TFF-3) were associated with injury to the 
proximal tubule. Changes in urinary cystatin C, total protein, 
and β2-microglobulin were associated with glomerular injury. 
Changes in urinary clusterin were associated with injury to the 
distal tubule. Changes in urinary renal papillary antigen-1 were 
associated with injury to the collecting duct. 
These qualified renal biomarkers can be used to facilitate drug 
development, as illustrated by decision algorithms such as those 
presented in Dieterle et al. (2010b). If a drug induces renal his-
tologic lesions in rats but has no effect on the levels of BUN and 
serum creatinine, the sponsor could evaluate whether appropri-
ate novel urinary biomarkers are diagnostic of the renal injury 
induced by the drug in rats. If the biomarker signal correlates 
with the evolution and reversibility of the histologic lesion, the 
biomarker would be considered diagnostic of injury in rats and 
could be used in defining the no adverse effect level (NOAEL) 
pathogenic) or a pharmacologic response to a therapeutic in-
tervention (Biomarkers Definitions Working Group, 2001). The 
goal of biomarker qualification is to improve the efficiency of 
drug development by achieving a consensus across CDER on 
the interpretation of biomarker measurements used in drug ap-
plications. Historically, biomarkers have come into common use 
in an unstructured manner as the result of many separate studies 
published in the scientific literature over many years. A formal 
process for the qualification of biomarkers should reduce the 
use of animals by eliminating redundant studies conducted by 
sponsors who seek biomarkers for common purposes, particu-
larly for safety. Such a process is likely to be more efficient and 
transparent than qualifying biomarkers on a case-by-case basis.
The end result of CDER’s biomarker qualification is a conclu-
sion that the biomarker results within the stated “context of use” 
can be relied upon to have a specific interpretation and applica-
tion in drug development and regulatory decision making. Al-
though a biomarker (i.e., the substance or analyte being meas-
ured) can become qualified, this qualification is not equivalent 
to approval of a specific test or diagnostic device for perform-
ing the measurement. Different assays can be used to measure 
a single biomarker as long as each assay has been demonstrated 
to measure the same analyte, and each assay has been appropri-
ately validated. Once a biomarker is qualified, it can be used in 
the qualified context in drug applications. However, the use of 
a qualified biomarker depends upon the absence of 1) serious 
study flaws in collecting data, 2) application of the biomarker 
outside the qualified context of use, and 3) any new scientific 
evidence that conflicts with prior conclusions. 
CDER initiated the development of its qualification process 
with a pilot program that involved two submissions for urinary 
biomarkers of nephrotoxicity in rats. The first pilot submission 
made by the Predictive Safety Testing Consortium (PSTC) in 
2007 resulted in qualification of seven urinary biomarkers in 
2008. The second pilot submission made by the International 
Life Sciences Institute (ILSI) / Health and Environmental Sci-
ences Institute (HESI) Nephrotoxicity Working Group in 2008 
resulted in qualification of two urinary biomarkers in 2010. One 
biomarker was qualified in both groups. Based on experience 
with these pilot submissions, a formal biomarker qualification 
process was proposed and approved by the CDER in 2009.
The framework for qualification of biomarkers and other drug 
development tools (DDTs) is provided in a CDER draft guid-
ance on DDTs released in 2010 (US FDA, 2010). This guidance 
discusses two types of DDTs, biomarkers and Patient Reported 
Outcome instruments, and it describes the process of working 
with CDER as well as a process for consistent scientific evalu-
ation. An appendix to the guidance will be issued for each DDT 
qualification. This process involves publication of a notice of 
qualification in the Federal Register and posting of the qualifica-
tion letter on the CDER website.
the guidance on DDts does not discuss evidentiary stand-
ards for qualification. The evidentiary standards (the type and 
amount of data) needed to support qualification of a biomarker 




used to generate systems biology pathway models based on the 
in vitro signals that we identify so that they can be understood in 
the context of the larger biology? How do we translate from the 
in vitro concentration that we are using to an expected in vivo 
exposure, and how do we make these predictions? 
Boekelheide also asked attendees if they felt that eBt has a 
role in defining what these components and modules are, as well 
as what the process is. Does EBT provide a first step in framing 
the structure that helps us find a way to make these new assays 
work for developing information that we consider to be inform-
ative and relevant for humans? This is a different question than 
asking whether an assay works, he pointed out. It is pondering 
the structure required for all of the different kinds of techniques 
that we require in order to make extrapolation work. Is there a 
process we as a community can agree upon that culminates in a 
larger sense of what that structure needs to be, he asked.  
the sources of information for setting up our analysis of these 
structures, as well as the particular assays that will support them, 
include scientific articles and databases, Boekelheide continued. 
In general, there are very few scientific articles published in this 
area, which raises the question of what to do in the absence of 
information from published sources.
One potential source, Boekelheide said, is the large databases 
that now serve as repositories for information collected by new 
testing methods; these are growing by leaps and bounds. If you 
publish an article that uses a microarray approach, most journals 
require you to dump all of that microarray data into a publicly 
accessible database, he noted. The question is what to do with 
the huge amounts of freely accessible data now available. Is it 
the job of an evidence-based toxicologist to use that kind of 
information, he asked. If so, who gets paid to make use of what 
and how is it used?
Another issue Boekelheide raised is the fact that, unlike the 
medical field, there is currently very little commonality for col-
lectively assessing information in toxicology. Every published 
paper is likely to use a different cell line, a different platform, a 
different array approach, and/or a different species from which 
the cell was derived, he lamented.
One possibility for integration is to take the pathways ap-
proach, Boekelheide said. Biological pathways and toxicity 
pathways are common across species, although there will of 
course be differences in details. But this interpretation relies on 
an assumption that he predicted will be Sisyphean to prove, that 
pathways will be the same and coherent.
Another key issue is how to ensure that the evidence-based 
approach will provide the appropriate level of detail to be in-
formative about the information being generated. He viewed the 
case studies presented in the workshop session in question as 
lacking detail about some important data, such as the quality of 
the messenger RNA, which is going to strongly influence the 
signal integrity that one gets out in these platforms, he said. 
Boekelheide also asked participants to consider whether ev-
idence-based approaches can serve to guide the field prospec-
tively as it designs new assays and tools, rather than simply be 
applied to the assessment of previously generated data.
Boekelheide concluded on a hopeful note by suggesting the 
evidence-based approach may allow bioinformaticians and stat-
and the starting dose of the drug for first-in-man clinical studies. 
If a human assay is available for the particular biomarker, the 
sponsor could propose to monitor the biomarker in the clinical 
trial. If the biomarker was not diagnostic of injury in rats, then the 
proposed clinical trial could be delayed or a higher safety margin 
(lower starting dose) would be needed to initiate the trial.
A search of the CDER electronic document database provides 
evidence that the qualified urinary biomarkers are being used 
in drug regulation. Documents were obtained with reference 
to the qualified urinary biomarkers in regulatory reviews and 
other documents finalized from 2006 through mid-July 2011. 
Based on the number of documents obtained for each biomar-
ker, the documents referring to KIM-1, clusterin, or cystatin C 
were examined in more detail. The number of regulatory docu-
ments with references to these biomarkers increased after 2008, 
the year the biomarkers were qualified. Although references to 
these biomarkers were found in documents from all divisions 
within CDER, two divisions (Division of Cardiovascular and 
Renal Products and Division of Metabolic and Endocrine Prod-
ucts) have produced the largest numbers of documents with 
references to these biomarkers. The references to the qualified 
biomarkers were found not only in reviews but also in com-
munications with sponsors, such as meeting minutes and advice 
letters. Therefore, these qualified nephrotoxicity biomarkers are 
being used in CDER regulatory activities. 
In addition to the qualification of nephrotoxicity biomarkers, 
cardiac troponins were qualified for nonclinical use on Febru-
ary 23, 2012 based on a submission summarizing the publicly 
available literature and CDER’s experience with the clinical and 
nonclinical use of cardiac troponins. Of the submissions still in 
the qualification process, one submission is nearing the end of 
the review phase, and fourteen submissions are in the consulta-
tion and advice phase. Some of these submissions are for clini-
cal biomarkers. The experience obtained thus far is being used 
to refine the process of qualification by formalizing written poli-
cies and procedures within CDER. Hopefully, a refined qualifi-
cation process, as well as the qualification and use of biomark-
ers, will facilitate efficient drug development of an increasing 
number of safe drugs. 
 
4.2  Invited discussant Kim Boekelheide
Invited discussant Kim Boekelheide of Brown University, a 
member of the US EBTC Steering Committee, observed that the 
eBtC is intending to focus primarily on assessing alternative 
test methods, techniques, and tools for analyzing toxic effects, 
rather than considering the toxic effects of chemicals per se. 
Boekelheide rhetorically asked attendees if they can identify 
an approach that the scientific community is likely to agree upon 
for taking the new kinds of information being generated via 21st 
century toxicity testing assays and translating those into safety 
prediction for humans. The key issues have been raised before 
in the Toxicity Testing in the 21st Century report (NRC, 2007) 
and other forums, Boekelheide said. For example, what do we 
do about metabolism and QSAR databases in this new setting? 
What are the platforms that are useful and informative? How 
do we factor in important information such as human genetic 
variability and epigenetics? What computational tools can be 
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Judson discussed his thoughts on how an evidence-based ap-
proach might be used to develop a prioritization program like the 
U.S. EPA’s EDSP, a program that Wolf had discussed earlier (see 
Section 3.1). It would start with the hypothesis that chemicals 
to which people, fish, or frogs are exposed trigger perturbations 
to specific pathways. Because we believe that these pathways 
could lead to adversity, we want to test these triggering chemi-
cals sooner rather than later. The next step is to look for evidence 
linking the pathways to perturbations or adversity. An evidence-
based approach can be used to evaluate this. However, you need 
to make certain that the exposure is relevant and that the pharma-
cokinetics are evaluated, he said. Only if the exposure, pharma-
cokinetics, and pathways come together in an appropriate way 
can you get all the way from exposure to adversity. 
there is currently a paucity of data for evaluating this, Judson 
said. We do have exposure measurements, some incidence in-
formation about what is in the nation’s waterways and air, some 
chemical use information, and details about how much is manu-
factured. We have some information about fate and transport 
properties, and we can ask if they are similar to chemicals that 
we already know a lot about. We also know that some of these 
chemicals have endocrine effects. These are all classes of infor-
mation that we can throw into this process, he said.
Many datasets are available for use as sources of unbiased 
data, such as the ACTOR and PubMed, Judson said. EPA’s Inte-
grated Risk Information System (IRIS) assessments for priority 
pollutants dataset, which constitute the gold standard for evalu-
ating chemical toxicity, may be amassed via an evidence-based 
process, he noted. However, because we have at least 10,000 
chemicals that we need to deal with, the IRIS would not be us-
able to evaluate them quickly enough because the tests take so 
long to be completed. 
Judson’s comments led to a discussion about EBT’s utility that 
many conference participants said they found helpful. Chapin 
observed that, with EBT, scientists could evaluate, for example, 
whether a method does a good job of identifying in vitro bio-
logical activity, and if the findings are transferable across labs. It 
could be used as a process for evaluating methods, he said.
4.5  Open discussion
Thomas Hartung explained that evidence-based approaches are 
a certain toolbox that can be applied, in principle, to any type of 
scientific question. It is a way of condensing information with 
criteria that are transparent, objective, and explicit. It requires 
tools that have not yet been developed in the context of the new 
toxicology. So EBT could address any question in toxicology 
– a method evaluation, condensing information on a given sub-
stance such as arsenic, a medical treatment problem in clinical 
toxicology, etc. 
One thing that makes EBT different is that the question is 
very clearly defined, he explained. Usually it is a limited, very 
precisely defined issue for which all relevant studies are col-
lected. EBT is also different in that the process, not the content, 
is in the foreground. It is about constructing a process that is 
judged to be the best one possible at the time it is created. Ide-
ally, the process itself is peer reviewed in advance to ensure that 
it is sound. 
isticians to systematically mine the large amounts of microar-
ray information now in the public domain. This may allow the 
information to be manipulated, integrated, and understood in 
ways not previously possible.
 
4.3  Invited discussant Robert Chapin
Robert Chapin of Pfizer – a member of the US EBTC Steering 
Committee – speculated about how EBT would look in prac-
tice. One area where it may have promise is in comparing as-
says such as those for estrogenicity reporters. The existence of 
only 5 or 10 estrogenicity reporter assays suggests that there is 
a reasonable “substrate” for an EBT kind of approach for, say, 
identifying performance criteria, he said. 
Because Chapin works in developmental toxicology, he said 
he has hoped EBT will be able to have an impact in that field. 
However, he noted that in the last 10 years, only 10 to 15 pa-
pers have reported on purported improvements on some vari-
ant of assays using zebrafish, whole embryos, and/or stem cells. 
this may violate one of the fundamental operating criteria of 
evidence-based approaches: that there should be a sufficient 
number of papers out there that all look at the same method and 
come up with x, y, or z performance characteristics to allow 
them to be compared, he said. 
In this regard, Chapin asked Scherer (of the Cochrane Collab-
oration) how evidence-based medicine handles situations where 
there are not enough papers using the same method. She noted 
that Cochrane has an “empty” category; that in itself is a finding 
because it says that there is no evidence for a given question. 
She also pointed out that the Cochrane process evaluates medi-
cal evidence for heterogeneity. If the amount of heterogeneity is 
deemed critical – which she thought could be analogous to the 
situation Chapin described – the process stipulates that the data 
cannot be combined analytically. However, the Cochrane process 
does allow for a “narrative” review in such situations, whereby 
the results from the studies can be presented thematically. 
Many of the papers that scientists may want to assess together 
will take the form of gene analysis reports, Chapin continued. 
Maybe one of the most valuable contributions that an EBT 
group could provide would be to encourage statisticians, model-
ers, and bioinformaticians to dive into the data and analyze them 
for commonalities. They may be able to find a new common 
denominator across studies that initially appear to have none. 
Chapin concluded that the weakness of the evidence-based 
approach for some areas of toxicology is that there may not be 
enough similarity in the reports in the literature to start the proc-
ess, a concern mentioned by Boekelheide. To get around this 
potential stumbling block may necessitate having experts comb 
through the huge volumes of available array data to bring com-
monalities to light. 
4.4  Invited discussant Richard Judson
Richard Judson of the U.S. EPA, a member of the US EBTC 
Steering Committee, was the third and final discussant. He ac-
knowledged that coming into this meeting he did not perceive a 
difference between EBT and validation. He said that the meet-
ing had made clear to him that validation could be one of many 
focal points of EBT.
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ments about it. In this way, Silbergeld argued that it is prefer-
able to the current approach taken by the agencies charged with 
shepherding toxicology data. 
Hartung added that a lot of this is about condensing informa-
tion so that it can be digested by the scientific community. As an 
example, he pointed out that toxCast data is particularly useful 
for identifying toxicity pathways. EBT is useful for comparing 
how the ToxCast data identifies such pathways with ones identi-
fied via other methods, such as the Hamner approach using case 
studies. 
The initial utility of EBT will be to build confidence with the 
public and stakeholders that what you are doing is relevant for 
decisions that are going to have great impact, Silbergeld said. 
Rashid Shaikh of the Health effects Institute expressed con-
cern that the term “evidence-based” could be perceived as off-
putting, given that scientists already see their work as evidence-
based. He said that he perceived utility for EBT but also noted 
that implementing it will have its attendant challenges. For ex-
ample, he foresees the possibility of narrowing down the subject 
of interest so much that the result is a filter so fine that not much 
comes out of it. 
Silbergeld responded that it is possible to explicitly relax a 
filter if it becomes clear that it is allowing too few things to pass 
through. She added that she became an adherent of EBT due to 
her recognition that adopting it could have a positive impact on 
the scientific process. Cochrane has improved the practice of 
clinical trials enormously, she noted. The British Medical Jour-
nal also published a document detailing its utility for environ-
mental and observational epidemiology. 
Hartung said that a validation study is for eBt what a multi-
center, randomized clinical trial is for EBM. In other words, it 
provides the most valuable information, he said. EBT teaches 
its adherents about how to set criteria to identify and thus, indi-
rectly, how to produce high quality data.
Chapin noted that what the group is groping toward is a proc-
ess and trying to find what the process will look like for hauling 
together the pieces of data that will be allowable in discussing 
whether a test method is appropriately delivering what its devel-
opers say that it does.
Silbergeld stressed that framing the problem is key. 
Errol Zeiger, a consultant, voiced his developing understand-
ing that EBT can be applied to data regardless of whether it re-
sults from a new technology or an old technology. “We’re talk-
ing about how to deal with data to evaluate a situation, answer 
questions, and recommend decisions,” he said. Many workshop 
participants indicated their assent to these comments. 
George Woodall of the EPA’s National Center for Environ-
ment Assessment (NCEA) noted that his division is in charge 
of the IRIS assessments for priority pollutants, and many of the 
recommendations made during this session echo those made by 
the National Academy of Sciences for the IRIS assessment on 
formaldehyde. Those things are being integrated into IRIS, he 
noted. 
Nicole Kleinstreuer from the EPA’s National Center for Com-
putational Toxicology (NCCT) said that her center initially 
eBM also involves tools that are not generally used in toxi-
cology, Hartung continued. These tools are used to address the 
quality of the data. It also includes formal mechanisms for con-
densing information. 
Finally, there is a mechanism for making the information 
available so it is considered to be a resource of highest possi-
ble quality. Hartung expressed his hope that, in time, the EBTC 
would achieve a quality similar to that of the Cochrane Library,8 
which is known to use a rigorous process to ensure that all of its 
data is of very high quality. In this way, EBT holds promise for 
providing a higher quality than journal peer-review, which can 
vary depending upon who is tapped as a reviewer, Hartung said. 
What EBT is can change over time, just as EBM has changed 
and expanded over the years to become Evidence-based Health 
Care (EBHC), Hartung said.
Silbergeld reiterated an analogy from her presentation, com-
paring EBT to a court of law. There are rules of evidence that 
guide how information can be presented to the court. Rules of 
evidence do not tell the judge what to decide, she stressed. What 
rules of evidence do, and their value, is in imposing order on a 
chaotic world of things that present themselves as facts.
The process begins with coming up with some criteria as to 
what are relevant, perhaps some key words, which would in-
form how you would extract the information in question from 
the databases where it can be found. Then you amass all the 
available data – say, 1260 studies on arsenic. From there, you 
apply criteria that determine whether or not you will go any 
further with some of the elements that came up in your search, 
perhaps study size, a specific type of cell, etc. The end result is 
your collection of evidence.
Next, you assess the amassed material for aspects that in-
crease your confidence in the findings. The evidence, with all 
its bumps and shining stars, is presented in the most transparent 
way possible. You want to have a way to compile the output, 
which could take many different forms, such as an odds ratio or 
a magnitude of change over a range of exposures, etc. This gives 
you a way to weigh the evidence, she explained. Then and only 
then can experts come in and make a judgment about what the 
evidence suggests.
Scherer added that the Cochrane Collaboration does not pro-
vide guidance as to how the evidence amassed by the process 
is to be used. It is up to the healthcare providers, insurance 
companies, consumers, and other interested parties to look 
at the evidence in the context of a specific patient and decide 
whether the evidence can be appropriately applied. “We do not 
make the judgment; we simply say here is the evidence,” she 
explained. The evidence does include conclusions about its re-
liability and the confidence that the Cochrane Collaboration 
has in the results. 
Silbergeld stressed that EBT would in no way replace the 
wisdom of everyone assembled at the workshop. “The expert 
judgment, experience, and wisdom of toxicologists and others 
involved in the endeavors we’re all sharing are infinitely valu-
able,” she said adamantly. What Cochrane does is separate the 
process of collecting the information from those making judg-
8 www.thecochranelibrary.com
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poses, and different entities may interpret it in different ways 
depending upon their needs. 
Martin Stephens of Johns Hopkins University, who is a mem-
ber of the US EBTC Steering Committee, ended the session by 
showing a slide that was originally prepared for EBM by Scher-
er, and which he is translating to EBT. It gives an overview of 
the processes of generating evidence, as well as gathering and 
assessing published studies. Different people are involved with 
each step; industry, government, and academic labs generate the 
evidence; the data generators themselves can gather or assess it, 
as can members of the EBTC or others. Others can take it and 
integrate it into policy (if appropriate), including whomever in 
industry or government makes decisions. In the end, you have 
the application to public health. 
Once an EBT assessment has been completed, it can also 
feedback and inform how new data gets generated and the types 
of studies that are conducted, Stephens said. In that way EBT 
can help not only to condense existing data but help shape future 
studies, he concluded. 
5  Workshop Session 3:  
Potential Priorities for the Evidence-based 
Toxicology Collaboration 
This session featured a presentation by Suzanne Fitzpatrick 
(see Section 5.1).
5.1  Twenty-first Century Validation Strategies – 
Can Evidence-Based Toxicology Play a Role? 9
The National Research Council report, “Toxicity Testing In 
the 21st Century: A Vision And A Strategy” (NRC, 2007), de-
scribed a new vision and strategy for toxicity testing that would 
be based on human biology rather than animal biology and 
would be less expensive and time consuming. This vision also 
involves a strong commitment to the 3Rs – replacement, re-
duction, and refinement of animal use in experiments. Being 
responsive to this progressive scientific perspective would ne-
cessitate moving forward to develop, validate, and incorporate 
alternative toxicological test methods into the federal regula-
tory framework. 
As stated in the NRC report, “[c]hange often involves a piv-
otal event that builds on previous history and opens the door to a 
new era.” The publication of the NRC report itself was the “tip-
ping point” for a change in toxicology, but validation of these 
new methods for regulatory use will be the critical component 
in ensuring the vision’s success. Toxicologists have the unique 
opportunity to meet these challenges by looking at new ap-
proaches, new collaborations, and new ways to take advantage 
of 21st century technologies. 
Current formal approaches to validation involve lengthy and 
expensive processes that require validating in vitro data from a 
single assay against in vivo data. These approaches are not rele-
vant or even feasible for the new pathways and endpoints being 
measured with high-throughput and high content methods. 
identified the assays used to produce ToxCast data by using an 
EBT type of approach. Those assays come from a huge range of 
different platforms, including complex cell cultures, human pri-
mary cells, zebrafish, and stem cells. Each platform is subject to 
rigorous quality control and quality assurance. In a way, we are 
really trying to build up our body of evidence, she said. Klein-
streuer works closely with the predictive modeling project, and 
she is excited to apply this kind of framework to it. We’ve al-
ready started to build our basis of evidence from both the in 
vitro and in vivo sides, she said.
Hartung noted that toxCast is not a great case study for ap-
plying EBT because it has already been subjected to so much 
quality control. The important thing for moving forward is the 
commitment to be systematic, objective, and transparent, he 
said. We desperately need to be objective and discuss biases, 
he said. 
Many of the tools developed for EBM will fit quite well with 
what toxicologists do, Hartung continued. Systematic reviews 
can be applied; data appraisals are now under development; 
meta-analyses haven’t yet been done, but they’re coming; and 
test assessment methodologies can help improve toxicology, he 
said. 
Scherer pointed out that the area of research synthesis is 
quite a new field. Systematic reviews weren’t around before the 
1980s, she said. What you are struggling with is a method for 
research synthesis in your field. No one has done this before – 
that is why it is so difficult. 
A part of Cochrane that many people do not know about is 
the existence of methods groups, Scherer said. They do studies 
on how to carry out the elements of a systematic review. For 
example, an information retrieval group goes through and de-
velops search strategies. They figure out the best way to search 
for a particular kind of study. There is also a bias methods group 
looking for potential biases. Another group focuses on diagnos-
tic test accuracy, and one focuses on statistics. “This is an ex-
citing time for toxicology because you’re right on the edge of 
developing these methods,” Scherer said. 
Any kind of question can be addressed using an evidence-
based approach, she reiterated. The question is critical. It is the 
foundation for how you conduct your search and how you ap-
praise the studies that are going to be included in your review. 
Mike Holsapple of Battelle, who is also a member of the US 
eBtC Steering Committee, pointed out that the draft eBt mis-
sion statement suggests that people will use the eBt method 
both to sort through the available data and to judge it to facili-
tate robust decision making, which is at odds with the Cochrane 
approach. James Freeman, who chaired this workshop session 
and is a member of the US EBTC Steering Committee, pointed 
out that, historically, toxicologists did everything from invent-
ing the tests to running them and creating risk assessments. 
Toxicologists are used to evaluating their own work, he said. 
Silbergeld noted that some kind of division of labor is likely to 
be useful, and it seems to have served the Cochrane Collabora-
tion. Hartung said that once the evidence (or the absence of 
evidence) has been mapped it can be used for a variety of pur-
9 This section is based on a paper prepared for the proceedings by Suzanne Fitzpatrick and Abigail Jacobs.
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give regulators the needed evaluative procedures to judge the 
quality of new toxicological tools through the use of EBT’s sys-
tematic reviews and meta-analyses.
Systematic reviews carried out in a regulatory context must 
have the ability to look at proprietary data in a transparent man-
ner, while keeping the data confidential and addressing the open 
literature as well. Often regulators are criticized for not using 
data from the published literature. Applying systematic and 
meta-analysis approaches to the published studies in journals 
could assist regulators in incorporating these data into regula-
tory decisions.
There have been some objections to using EBT on the grounds 
that toxicologists already use evidence in assessing causation 
and reaching regulatory decisions. However, toxicologists 
should not let semantics turn them off to this approach. System-
atic reviews would offer a complete and rule-based analysis of 
data with conclusions that are transparent enough to be repro-
ducible. 
What can the EBTC do to begin promoting the use of ev-
idence-based reviews of in vitro toxicology test methods for 
making safety decisions for human exposure? A prerequisite 
is to develop a strong coalition of scientists from government, 
academics, and industry who are committed to working together 
to facilitate change. Agreement on a shared vision and a gov-
ernance plan will give the EBTC a strong foundation to build 
consensus.
Single tests alone, even if highly sensitive or specific, can no 
longer provide an appropriate assessment of a chemical’s toxi-
cological properties. Toxicologists will need to incorporate in-
formation from many diverse sources – omics, animals, tissue 
culture, engineered organ systems, in silico, etc., into integrated 
testing strategies. The EBTC should help to identify the critical 
questions that need to be addressed when assessing the safety of 
products. These questions undoubtedly will differ between reg-
ulatory agencies and even within the same regulatory agency. 
The EBTC could then develop draft evidence-based criteria for 
integrating data from different sources to assess the relevance 
to humans. How much data are needed to give regulators con-
fidence in a new method? The answer will differ depending on 
where the method is incorporated into the regulatory paradigm.
The EBTC should identify both short and long term goals 
for addressing the issue of validation of new pathway-based 
methods. A good starting point might be the drafting of criteria 
for the validation of screening methods, where the levels of 
false negatives and false positives are not as critical to safety 
assessments. 
Evidence-based methods can provide more than a kind of 
quality assurance for new methods. They also can be used to 
synthesize the toxicological data for a risk assessment. Test cas-
es could be developed, comparing the results of evidence-based 
assessments with traditional risk assessments to see which gives 
the most clarity to assessing a product’s safety. 
Workshops to encourage dialogue and consensus need to be 
ongoing to gain confidence in the new validation strategies. 
Regulators need to clearly articulate the level of performance 
Consequently, applying a “one size fits all” approach to val-
idation is not conducive to the rapid incorporation of emerg-
ing science or technology into the regulatory decision-making 
framework. As new safety testing evolves, new approaches to 
demonstrating that a test is reliable and relevant for a particular 
purpose must also evolve. 
An example of a new validation strategy is the FDA Drug 
Development Tool (DDT) Qualification Process (see Section 
4.1). Qualification is a regulatory conclusion that, within the 
stated context of use, the results of an assessment with a DDt 
can be relied upon to have a specific interpretation and applica-
tion in product development and regulatory decision making. 
Once a DDT is qualified for a specific context of use, industry 
can use the tool for the qualified purpose during product devel-
opment, and FDA reviewers can be confident in applying the 
DDT without the underlying supporting data. The FDA DDT 
Qualification Program involves a “fit-for-purpose” qualifica-
tion. It is an objective, science-based approach for evaluating 
the relevance, quality, and reliability of a biomarker based upon 
its intended use, for example, a test method used as part of a 
screening program or a definitive surrogate endpoint in a pivot-
al clinical trial. Details about the FDA’s qualification program 
are available online.10 
there is a pressing need to develop and use a structured 
evaluative process for new toxicology tools similar to the DDt 
biomarker qualification process. This process would consist of 
uniform, objective, science-based criteria for systematically de-
termining data relevance, quality, and reliability. Once novel, 
cutting-edge methods have been evaluated and incorporated in 
the toxicological toolbox, data on a chemical’s effects from new 
and existing methods from all relevant studies should be com-
prehensively reviewed, given appropriate weight, and integrated 
in a transparent manner. The resulting document would describe 
a robust, biologically plausible understanding of the mode of 
action of a chemical and the potential hazards and risks that ex-
posure to the substance could pose to humans and to wildlife. 
Regulators must ensure that their toxicological toolbox keeps 
pace with advances in science and technology. But regulators 
also must determine how much evidence is sufficient to judge 
that a new tool is qualified to inform safety decisions that poten-
tially affect millions of consumers. There is a delicate balance 
between ensuring safety and avoiding restrictions on valuable 
products; this is a continual, unique, and demanding challenge 
for regulatory agencies. Any advances in validation must recog-
nize these competing demands that regulators face.
It is now clear that in vivo animal studies cannot be the gold 
standard that we qualify new toxicology methods against. Regu-
lators must determine the relevance of in vitro results to what 
occurs in humans rather than the concordance of that data to 
what occurs in rodents and other test animals.
A key aim of the eBtC is to advance 21st century toxicology 
by translating the principles and approaches of Evidence-based 
Medicine (EBM) to the evaluation of emerging toxicological 
testing methods. Structured reviews of existing evidence are a 
key feature of eBM, and translating this to toxicology could 
10 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/default.htm
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for the group varied over eight orders of magnitude, which he 
said “is what you’d expect – it happens in nature.” This gives 
you a distribution to work with without doing a single toxic-
ity test, he said. With some targeted testing, you have a good 
chance of understanding exactly where your chemical might be, 
he contended.
Pastoor noted the importance of comparing the exposure that 
people have to a chemical to the doses associated with toxic-
ity. For example, if you know that only a relatively high quan-
tity of a given chemical is likely to be toxic, and the quantity to 
which someone is likely to be exposed is much lower, you can 
feel pretty certain that it is unlikely to cause harm. In a situation 
where there is overlap between the dose likely to be toxic and the 
quantity to which people are likely to be exposed, you can refine 
your exposure assessment by targeted testing. You can also do 
the same thing for the hazard, he said. By doing so, you get a 
better idea of the gap between exposure and toxicity, he said. 
“Let’s get out of the rut,” Pastoor concluded. The issue at 
stake is the protection of human health. “When we’re talking 
about priorities, we’re really thinking about how we use prior 
knowledge to understand things so we don’t have to kill ad-
ditional animals in a pointless effort to try to refine information 
that we really don’t need.” 
 
5.3  Invited discussant Olga Naidenko 
The comments of Olga Naidenko from the Environmental 
Working Group reflected a societal view of chemicals manage-
ment and environmental stewardship. 
“Despite the best work that toxicologists have been doing up 
until now…. we are still stuck with what many people feel are 
… annoying and perhaps even intractable problems,” she la-
mented. The process for screening endocrine disrupters is not 
very effective, occupational chemical exposure in the U.S. is 
not adequately assessed, and the best science is not being used, 
she argued. 
Naidenko said that she agreed with a key point that Fitzpatrick 
made in her white paper: “The ability of researchers to develop 
and deploy biological profiling and high-throughput/high con-
tent methods has outpaced the ability of regulatory agencies to 
apply traditional method validation approaches for demonstrat-
ing relevance.” In fact, Naidenko said she felt that “the abil-
ity of researchers to develop and deploy new chemicals has far 
outpaced the current ability of society to assure the safety of 
these chemicals for the long-term sustainability of the planetary 
society….” 
Naidenko also agreed with Fitzpatrick about the need to build 
a broad-based coalition of scientists who are willing to work 
together to facilitate change and encourage the use of eBt, as 
well as on the need to develop uniform, objective, science-based 
criteria for systematically determining the relevance, quality 
and reliability of new test methods. 
Naidenko made some suggestions about obstacles she per-
ceived to EBT’s implementation and how to overcome them. 
Anyone who has ever participated in a political coalition knows 
that actions of coalitions are strongly dependent on positions of 
their participants, which are in turn shaped by their experiences 
and values, she said. 
needed to be adequate for the method’s intended use. Draft 
guidance with notice and comment for public input can assure 
transparency in the new procedures. International collabora-
tions with complementary research programs could help vet 
these new strategies worldwide.
Investments in advancing new validation strategies for 21st 
century methods can enable regulatory agencies to better pro-
tect and promote the health of people in the United States and 
throughout the world. Moving towards evidence-based ap-
proaches to validation is challenging but essential to catalyzing 
change that would allow us to take advantage of revolutions in 
science.
5.2  Invited discussant Tim Pastoor
Tim Pastoor of Syngenta anchored his remarks to RISK21, a 
multi-stakeholder project that he is co-chairing. Organized 
through the International Life Sciences Institute’s Health and 
Environmental Sciences Institute (ILSI/HESI), RISK21 is fo-
cused on applying the new toxicology and exposure assessment 
tools for the 21st century, as defined by the landmark 2007 NRC 
report (NRC, 2007), to what he called a “risk context.” 
Pastoor expressed his belief that toxicology is at the brink of 
a huge change in how practitioners conduct risk assessments. 
The new technologies that are available, together with some of 
the new thinking and the impetus provided by the NRC report, 
are a mandate to change. “We have dug a very deep hole as 
toxicologists because everything is about hazard-based assess-
ment,” Pastoor said. He challenged the audience to begin think-
ing instead about an approach based on zones of safe exposure. 
In place of the conventional approach of initially determin-
ing what effects a substance causes, RISK21 posits that the first 
consideration should be how much someone might be exposed 
to, Pastoor said. If human exposure is minimal to none and there 
is evidence that the toxicity is very low, one might do toxicity 
testing very differently.
Are we ready to move toward an approach that is exposure-
based and focused on safety, Pastoor asked rhetorically. He em-
phasized the importance of using prior knowledge. The RISK21 
group is exploring the idea of systematically assessing the body 
of prior knowledge using Bayesian network analysis, such as 
the probability within a class of toxicity potency. 
Pastoor argued that the point estimates and calculations used 
to determine acceptable exposure, such as acceptable daily in-
take (ADI) and reference doses (RfD), suggest that there is a 
bright line between safety and lack of safety. The reality is less 
clear-cut. 
RISK21 also calls for employing targeted in vitro testing, 
in conjunction with pharmacokinetic (PK) data, to narrow the 
range of expected toxicity, Pastoor said. In other words, you can 
use prior knowledge to make an estimate of what your toxicity 
values are likely to be, as well as what the exposure is likely 
to be. “Why don’t you just do the studies that are necessary to 
refine that knowledge?” he asked workshop attendees.
RISK21 counsels using targeted in vivo studies, Pastoor said. 
He presented data from the RepDose database showing the dis-
tribution of no observable effect levels (NOELs) for 404 chemi-
cals in mmol per kilogram of body weight per day. The toxicity 
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cient data on high priority effects, Holsapple said. To amplify 
this point, Holsapple quoted from a recent editorial in Science 
by FDA Commissioner Margaret Hamburg (Hamburg, 2011), 
who was essentially suggesting that toxicology is somewhat 
stuck in the past, and we need to be moving forward. The FDA’s 
strategic plan calls for improving predictive models and mod-
ernizing toxicology to improve product safety, he continued.
Holsapple said that he was struck by how many people on the 
US EBTC Steering Committee observed that their understand-
ing of EBT was enhanced by the talks at the workshop. There 
is still a real lack of consensus by the Steering Committee on 
what EBT is and should be accomplishing, he observed. “We’re 
really struggling with what transparency means, in terms of how 
we’re going to move this forward,” Holsapple continued. Like 
Fitzpatrick, he felt that listening to Silbergeld and Scherer de-
scribe evidence-based science had greatly enhanced his under-
standing of the discipline. 
Holsapple said that he felt that members of the Steering Com-
mittee would benefit a great deal from an “EBT 101” type of 
introduction to the issue. This would help ensure that the am-
bassadors trying to advance EBT are all on the same page and 
articulating the same message, he said.
He said that he is also still struggling with the mission state-
ment. He said his current understanding of evidence-based ap-
proaches is that the process involves amassing all of the evidence 
on a narrowly defined subject and going through it very system-
atically, using a priori defined criteria. The analysis involves 
making sure the evidence is packaged in such a way as to clearly 
show that it presents the best “look and feel” for what the evi-
dence can present right now. “The important thing is that those 
involved in the evidence-based approach don’t make the value 
judgment; they don’t say ‘yes’ or ‘no’ or it’s ‘blue’ or ‘green.’ 
The evidence is handed off to someone else,” he summarized. 
Holsapple believes the EBTC needs to develop a communica-
tion strategy to focus on ensuring that this evidence-based ap-
proach is understood. We have to become the ambassadors to 
champion that, he said. A key target audience is the public. “If 
we don’t bring the public along, they’re going to be blindsided, 
and they’re not going to be happy,” Holsapple said. He feels 
that the eBtC needs to engage in the same kind of outreach to 
other stakeholders because they are going to be very important 
to realizing the coalition’s goals.
5.5  Open discussion
Ellen Silbergeld complimented the panel of speakers for mov-
ing the group to think about the directions, actions, and oppor-
tunities for productive collaborations. She agreed with Holsap-
ple that bringing along “the broader community and persons of 
interest will be absolutely critical.” 
A wide-ranging discussion of issues related to exposure, dose, 
and safety ensued, mostly in response to Tim Pastoor’s invited 
commentary. Session chair Rodger Curren, a US EBTC Steer-
ing Committee member, asked participants to try to focus on the 
issues that the EBTC should be looking at in terms of validation 
and understanding how EBT methodology can be supplied. 
Richard Becker pointed out that workshop participants seem 
The solution to these pitfalls is transparency about values and 
goals, Naidenko said. Open discourse about values ensures that 
regulators and stakeholders cannot hide behind “science made 
me do it” statements, she said.
Naidenko raised concerns about the white paper’s statement 
that, as new safety testing evolves scientists will develop “uni-
form, objective science-based criteria.” She pointed out that 
values and the perception of what is “safe” and what constitutes 
an “unacceptable risk” vary within society, between societies, 
and between different economic groups, such as workers, con-
sumers, parents, the affluent, and those who are economically 
challenged. 
Naidenko asked participants to consider “the balance of our 
goals in the economics/ecology continuum.” How do we handle 
risk-risk tradeoffs, she asked. For example, certain degrees of 
public health protection may entail the loss of jobs. This begs 
the question of what we can afford. 
“We of course believe that our science is objective, but science 
is very much embedded in the society that produces the knowl-
edge,” Naidenko said. Understanding the nature of knowledge 
is essential for helping us avoid errors in thinking, she said. In 
addition to providing useful insights into the issues facing toxi-
cologists interested in using 21st century tools, the study of the 
sociology of science and progress may help us save time and 
money, Naidenko suggested.
Naidenko commented that what toxicologists are trying to do 
via EBT is inherently more difficult than what medical science 
has achieved through the Cochrane Collaboration. While Co-
chrane is focused on a better way to do good by curing patients, 
the toxicology collaboration may be seeking to determine the 
scientifically, ecologically, and economically acceptable level 
of harm, she observed. 
We cannot do EBT successfully unless society jointly, trans-
parently decides on its values along the economic-ecological 
continuum, she contended. She said she agrees with Fitzpatrick 
and Pastoor that we do want to use prior knowledge. We do 
want to study the literature on previous stumbling blocks, such 
as BPA, to determine what went wrong and what we can learn 
from those experiences. We don’t want to spend millions of dol-
lars to end up with something that no one is satisfied with, she 
concluded. 
5.4  Invited discussant Michael Holsapple 
the third invited discussant, Michael Holsapple of Battelle and 
a member of the US EBTC Steering Committee, agreed with 
the points that Fitzpatrick raised in her white paper and said he 
would be presenting some of the issues that the EBTC will need 
to tackle in the future. 
He emphasized that toxicologists have many topics of inter-
est, but few have the potential for having a greater impact on the 
science of toxicology than the challenge of using 21st century 
tools, or Tox21c. He said he feels that if toxicologists do not 
embrace Tox21c and try to move it forward, the discipline is in 
danger of become increasingly marginalized.
The current “menu-driven” approach to toxicology provides 
too much information about items of low interest and insuffi-
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synopsis to make a decision. “It would be a way to systematical-
ly review evidence by the same transparent process,” she said.
Holsapple responded that one thing that was alluded to on the 
previous day was for the eBtC to conduct some sort of case 
study. In other words, to use the process to analyze some data 
that presents a daunting challenge and then have someone look 
at the data and make some sort of a determination as to whether 
or not the evidence-based process proved useful.
Silbergeld said that she did not think it made sense to try to 
tackle a daunting challenge. Pick something that a crisp ques-
tion can be formulated to address, she urged. Ideally, this subject 
should be one that has been the focus of as many papers as pos-
sible so there is a lot of evidence to bring to bear. The topic also 
should be one for which researchers hope that it is possible to 
get somewhere by sifting through the evidence systematically. 
Silbergeld again raised the analogy of a courtroom. “It’s not 
like a grab-bag of different charges and different laws. It’s a spe-
cific case for which evidence has been deemed to be admissible 
or not,” she said. “If the charge were different, then maybe dif-
ferent evidence would be admissible.” Formulating the question 
crisply is the key to success, she said.
Holsapple responded that, to him, picking a subject that was 
data-rich was part of what constituted a daunting challenge. 
“What’s necessary for EBT to get some kind of momentum is to 
demonstrate that we as a community can apply it and get some 
meaningful information from it.”
Fitzpatrick said that in drug development and qualification 
there is a “pre-EBT phase.” We come in for a consultation be-
fore all of the evidence has been generated to determine what 
kind of evidence is needed to give the regulators confidence, 
she said. 
thomas Hartung pointed out that what the group collectively 
learned yesterday was that evidence-based approaches are a way 
of handling information and condensing it. The process is so 
good that scientists can rely on the end product without going 
through all of the supporting information in detail. The process 
ensures that the evidence has been evaluated in a credible proc-
ess. By this we can help a lot of applied toxicology, he said. 
today we have heard some compelling calls for using the ev-
idence-based process for evaluating candidate drugs and pesti-
cides, Hartung added. It is clear that evidence-based approaches 
have the ability to condense information and ensure quality on 
all levels. What the presentations and discussions to date have 
shown is that one of the priorities for the eBtC is to sharpen the 
group’s understanding of what the tools do and do not deliver, 
he said. 
Hartung said that he was encouraged to hear that Fitzpatrick 
had already had positive experiences with applying some eBt-
like processes to BPA. “It’s most important that we now build 
from these types of cases,” he said. He said that EBTC has some 
mechanisms to fund some meta-analyses and studies. 
Hartung agreed with Holsapple’s statement about the need to 
produce a document that clearly explains what eBt does so that 
people are discouraged from using the label for whatever they 
think is cool in toxicology at the moment. Holsapple said that, 
in addition to defining what EBT is, any document produced 
to have different visions for EBT. If we think very broadly, there 
are probably different applications of evidence-based approach-
es that we should be thinking about. We probably also should be 
thinking about moving forward within some kind of consortium 
to address these, he said. One component of EBT that is top 
of mind is 21st century tools and validation strategies for these 
tools, per Fitzpatrick’s presentation. That may be one area the 
EBTC should consider focusing on, he said. 
Becker said that he thought the group needed to look carefully 
at the decision paradigm for which those tools are being devel-
oped and for which they are intended to be applied. That has to 
be integral to the way that we evaluate the data to establish the 
scientific confidence in that tool, he said. He noted that Fitz-
patrick said the FDA looks for the purpose for each methodol-
ogy within a regulatory decision-making framework. Similarly, 
Becker observed that Pastoor talked about an integrated Baye-
sian assessment approach that involves looking at knowledge 
and targeted evaluation using different methods to provide the 
information needed to make the decisions. 
Becker posited that the new technologies cannot be evaluated 
by divorcing them from the application for which they would 
be used. He therefore suggested that it is important to bring for-
ward the tools, together with the data and the context and the 
decision framework within which they would be utilized. 
Holsapple said that he felt of two minds about his response 
to Becker’s comments. “I agree that we need to understand the 
context,” he said. “I think that’s essential.” He said that he did 
not think it made sense to try to evaluate fitness for purpose for 
each of the many assays now available. Instead, he he thought it 
made sense to get a fit for purpose for a series of assays. 
On the other hand, he pointed out that, as he understood the 
evidence-based approach, it is a tool that can be applied to any 
question. You define the question up front and define the criteria 
a priori to answer any of these questions. This potentially broad 
scope notwithstanding, Holsapple argued for the eBtC to go 
on record as being involved in validation as one of its major 
activities. The other alternative is the more general goal of pro-
moting the beauty of trying to conduct meta-analyses and very 
systematic reviews and bring evidence-based approaches into 
toxicology, he said. 
these are two different paths, although they are not necessar-
ily mutually exclusive, Holsapple said. 
Fitzpatrick asked if EBT could be used to frame the question 
to see if evidence-based approaches could be used to evaluate 
fit for purpose. As an example, she said: “is this method, in this 
regulatory context, able to give us assurance that the answer 
is what we want?” If the question was framed tightly, it might 
result in a lot of EBT evaluations at first, but it would enable 
people to evaluate all of the evidence.
Holsapple said that he felt it would work as long as you were 
setting a priori criteria to address the question. However, Hol-
sapple said that the answer of whether the fit was good or not 
would go beyond what the evidence-based process is designed 
to achieve.
Fitzpatrick said her idea was to use evidence-based approach-
es to analyze the question, and the regulator would look at the 
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absent allows reviewers to have a common set of transparent 
reference points, she said. 
Rob Wasserman of EPA’s IRIS program said that his program 
is in the process of developing criteria for what constitutes ac-
ceptable evidence. He said that, to him, it seems that the first 
thing for the EBTC to do would be a comparison involving cri-
teria that already exist, rather than a case study. 
6  Workshop Session 4:  
Governance and work processes for the Evidence-
based Toxicology Collaboration 
This session featured a presentation by John Fowle.  
The following section (6.1) is a summary of that presentation.
6.1  Governance and Work Processes of the 
Evidence-Based Toxicology Collaboration
John Fowle, who recently retired from the ePA, discussed 
key points to consider as options for establishing governance 
and work processes for the EBTC in a white paper. The options 
are modeled after the governance and work processes of the 
Cochrane Collaboration and its approach to EBM. 11 
the goals of the eBtC include fostering the development of a 
process for quality assurance of new and traditional tests for the 
assessment of safety in humans and the environment, as well as 
providing guidance on evaluating evidence from new and exist-
ing tests when assessing chemical safety. The key methods used 
by the Cochrane Collaboration include systematic reviews of 
relevant literature, such as inclusion/exclusion criteria for pub-
lished studies and meta-analysis of data. These approaches can 
be applied to the EBTC, and in addition, the Cochrane Collabo-
ration approach to governance offers a model for shaping the 
nascent organization’s operations and policies. 
The EBTC, in order to be successful, will need to reach the 
hearts as well as the minds of many individuals in many differ-
ent areas of expertise to secure stakeholders’ time and effort to 
systematically identify and review the toxicology literature. The 
organization also will need people to serve on teams to write 
reports of the findings; to work to capture the reports in databas-
es and electronic libraries; to help train others; to hold periodic 
meetings; and to contribute to all the many other tasks that will 
be required if the organization is to achieve its vision. This means 
that “buy-in” is needed and that simply copying the Cochrane 
Collaboration approach to governance and work processes and 
applying it wholesale to the EBTC likely will not work. 
Kotter (1996) identifies eight steps to leading change. These 
include establishing a sense of urgency, creating a guiding coali-
tion, developing a change vision, and empowering broad-based 
action. Kotter also extolls the value of generating short-term 
wins at the outset of the process. 
Fowle consulted a number of sources of information on the 
establishment of governance, policy, and procedures for a non-
profit organization such as the EBTC. “The Basics of Forming a 
Nonprofit” checklist from “Nonprofit Law and Governance for 
should also make clear what it is not. Perhaps a flow chart could 
be used to show this, he said. 
Hartung said that Naidenko’s comments also made clear that, 
in addition to aiding the toxicological community, eBt may 
help with outreach to other stakeholder groups and the public. 
High quality, condensed information could appeal to many oth-
ers and could be used to inform many processes, he said. 
Sebastian Hoffmann of seh consulting, and a member of the 
european HtPC Steering Committee, said that from the eu-
ropean perspective, it should be a priority for EBT to be used 
not only to assess individual tests but also to develop testing 
strategies. He acknowledged that EU and U.S. priorities may 
differ. 
Naidenko said that it may be important for the group to con-
sider how to get stakeholder buy-in as early in the process as 
possible. She also observed that doing case studies and publish-
ing them early on would be a foundation for moving forward.
Gillian Griffin of the Canadian Council on Animal Care 
pointed out that the 8th World Congress on Alternatives and 
Animal Use in the life Sciences, held in Montreal last summer, 
resulted in a declaration on synthesis of evidence. She noted 
that conferees balked at calling it a declaration on systematic 
review, in part because people in the audience were concerned 
that we really did not have enough in the literature that would 
enable us to be able to do a systematic review. Because this is 
an iterative process, as we go forward, the information pub-
lished in the literature becomes richer and we are able to ap-
ply it to do better systematic reviews. She said she was very 
excited that eBt also is moving in that direction and noted that 
a number of other fields are also doing so. Finally, she said she 
also felt that public engagement was key. 
Doug Keller of Sanofi said that, as the EBTC defines itself 
and starts to tackle case studies, it’s essential to establish itself 
as an unbiased organization. You don’t want to be perceived as 
a group with an agenda to justify pathway-based methods or to 
replace animal use, even if that’s the eventual goal that many 
people have. The Steering Committee’s composition is helpful 
in that regard, but Keller stressed that the group’s credibility 
will be established by how it proceeds.
Hartung said that an important aspect of evidence-based ap-
proaches is that they provide many tools to help practitioners 
avoid bias and to ensure that it does not affect the quality of the 
end product. This is, in part, because the process does not allow 
for manipulation, he said. Where manipulation cannot be ex-
cluded, the process makes its presence as evident as possible. 
Silbergeld noted there are two kinds of bias. The first she de-
fined as the National Academies kind of sociological bias, which 
is based on where you stand from and where you sit. There is 
also bias that is related to how studies are conducted and how 
data are collected. That is to some extent independent of the first 
type of bias, she said. 
The whole reason for initially establishing a priori consen-
sus-based definitions is to avoid bias, Silbergeld continued. 
Defining the characteristics or aspects of a paper that increase 
our confidence when present and decrease our confidence when 
11 http://www.cochrane.org/
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reviewing data on chemical toxicity from multiple types of 
methods and integrating these data to inform decisions about 
chemical safety. In other words, how do you integrate data from 
animals, tissue culture, high-throughput tests, various “omic” 
technologies, in silico approaches, etc. when the results do not 
all point in the same direction? A final task implied by the draft 
mission statement is to apply evidence-based thinking to the 
various existing and new toxicity testing approaches, perhaps 
through an adverse outcome pathway approach, to build an ef-
ficient integrated testing strategy or to critique a proposed strat-
egy in an unbiased fashion.
A well thought-out and carefully crafted vision statement 
is just as important as a mission statement to an organiza-
tion. While a mission statement speaks to the “head,” a vision 
statement speaks to the “heart” by providing the members of 
the organization with a picture of how things could be in the 
future and how that is of value to them as individuals. The vi-
sion is a stretch goal to strive for. Effective vision statements 
are easily grasped by all, but are very difficult if not impossi-
ble to reach, because they are designed to stimulate continual 
improvement as well as to provide a sense of purpose and a 
common goal.
to aid the eBtC leadership as they develop a vision for the 
organization, Fowle posed the following questions, derived 
from the Cochrane Collaboration’s retrospective analysis13:
– What is the organization (what are our aspirations for it)?
– Who does it serve (who are our customers)?
– Who wants what, when, how (what are the needs and expec-
tations of our stakeholders)?
– What will the organization provide (what are our products 
and services and what are the needs of third party users who 
will leverage our products and services into their own)?
– How are we differentiated from others?
– What is in scope?
– What is out of scope? 
A similar set of questions also could help the organization fine 
tune its mission statement, he pointed out.
Fowle also talked about the value of having a solid business 
plan and pointed workshop attendees to sources for advice on 
writing a business plan for a nonprofit corporation14.
Fowle acknowledged that properly developing and adopting 
a set of bylaws may seem too tedious and time consuming for 
many, given the enthusiasm to get on with advancing a new or-
ganization’s mission. However, in the spirit of “going slow to go 
fast,” he argues that it seems worthwhile to take whatever time 
is needed to place the organization on a firm footing to avoid 
misunderstandings, wasted time, and potential hard feelings in 
the future. He pointed out that “Robert’s Rules” comprehen-
sively classifies organizational rules based on their application 
and use and on how difficult they are to change or suspend (Jen-
nings, 2006). He recommended that the EBTC consider adopt-
ing Robert’s Rules of order, amending them as needed to meet 
the organization’s needs. 
Dummies” (Welytok, 2007) encapsulates advice from various 
publications:
To ensure the success of your nonprofit organization, you need 
to start with a solid foundation. Take a look at the following 
fundamentals checklist so your nonprofit is set up properly 
and legal issues are covered right from the beginning.
– Clearly define your mission and its scope
– Put together a business plan and system
– Adopt a set of bylaws
– Recruit a board 
– Hold an organizational meeting and define duties and re- 
   sponsibilities 
– File for tax-exempt status with the IRS12
– Register with your state 
– Get staff and volunteers in place
It is of critical importance to clearly define the mission and 
scope of any organization. Beginning with the end in mind 
(Covey, 1989) allows one to visualize what success will look 
like in the future by providing a “compass” to help direct the 
actions toward the ultimate goal. Thus, the EBTC’s mission and 
vision are key elements to consider when establishing proce-
dures for governance and work processes. They define what job 
the organization is to do and what a successful future would 
look like. All that the EBTC does will derive from and/or be 
evaluated against its mission statement.
In addition to the purpose and nature of the organization, a 
mission statement has implications for what the organization 
will do and how it will do it. A “to do” list can be developed 
from a properly crafted mission statement to guide the opera-
tions and governance of an organization.
Although the eBtC has not yet adopted a mission statement, it 
does have an early draft of one, which is admittedly overly long: 
The EBTC will facilitate the systematic, objective, and trans-
parent assessment of test methods to foster the increasing use 
of in vitro test data in making safety decisions for human ex-
posure. The EBTC will facilitate the adaptation/development 
and use of systematic reviews of methods to identify the most 
promising existing/emerging methods so that these may be 
used more broadly to generate critical safety data, [as well as] 
tools for data appraisal, meta-analyses, and test assessment 
methodologies, to identify the most promising existing/emerg-
ing methods so that these may be used more broadly to gener-
ate critical safety data. The EBTC also will apply these tools 
and approaches to the construction of testing strategies to en-
sure effective and efficient testing, as well as to the synthesis of 
data across studies to facilitate robust decision making.
this draft mission statement implies that the eBtC wants to 
add value to 21st century toxicology, as well as to traditional 
toxicology, by speeding the adoption of the best methods for 
next-generation safety assessment testing. It hopes to do this 
by adopting the tools and approaches of EBM as used by the 
Cochrane Collaboration. A primary activity implied by the 
draft statement is to sort out the difficult issues associated with 





in different locations to do the work of the organization. He sug-
gested that it would be possible to use questions employed by 
the Cochrane Collaboration’s retrospective analysis (see Sec-
tion 6.2) to elicit input from the interested stakeholders about 
what the EBTC should be, what it should look like, and what it 
should do to maximize the chance of success. 
Finally, Fowle offered two proposals aimed at triggering dis-
cussion and identifying action items and next steps:
1. Establish the EBTC as a nonprofit organization following the 
general approach outlined in this white paper. 
2. Base the EBTC Governance and Work Processes on the spe-
cific model of the Cochrane Collaboration, including its prin-
ciples, with modifications as appropriate to suit the EBTC 
needs.
6.2  Invited discussant Roberta Scherer
In response to the points John Fowle raised about the steps 
needed to create an organization and procedures for the EBTC, 
Roberta Scherer of the Cochrane Collaboration and Johns Hop-
kins University described how the Cochrane Collaboration has 
addressed these issues over the years.
She began by describing the evidence-based health care proc-
ess. Cochrane becomes involved after evidence on a particular 
medical topic – often in the form of a clinical trial – is gener-
ated. This evidence may or not have been published. Cochrane 
conducts a systematic review bringing the evidence together, 
synthesizing it, and doing a meta-analysis on it. This evidence 
is then used by professional societies or others to make deci-
sions. It also may lead to policy that is applied in the healthcare 
setting. 
Scherer underscored that the evidence is only one aspect of 
the situation. The other aspects – what are used to apply the 
evidence – are clinician expertise and patient values. 
Scherer noted that the collaboration’s name honors Sir Archie 
Cochrane, a British epidemiologist. In 1979, he criticized his 
profession for failing to “organize a critical summary by spe-
cialty or subspecialty adapted periodically of all relevant ran-
domized control trials.” In the 1980s, Sir Ian Chalmers, an ob-
stetrician, took up Cochrane’s challenge and organized a group 
of people to develop the Oxford database of perinatal trials. The 
group gathered all of the randomized trials having to do with 
perinatal care. 
In 1992, the British National Health Service funded the first 
Cochrane Center. The Oxford database of perinatal trials that 
Chalmers amassed in the 1980s served as a proof of concept 
study and precipitated the idea that systematic reviews of ran-
domized controlled trials testing various medical interventions 
could be done for all of medicine. The purpose of the original 
center was to facilitate the preparation of these systematic re-
views. The Cochrane Collaboration as such (not just a center at 
Oxford) was launched in 1993. 
The EBTC also will need to file for tax-exempt status with the 
IRS and register with the state, and Fowle presented sources for 
doing these things, as well as for hiring staff.15, 16, 17
The Cochrane Collaboration’s work processes and govern-
ance are described in the “Newcomer’s Guide” on the Cochrane 
Collaboration website.18 Further details about governance and 
work processes can be found in The Cochrane Manual.19 Co-
chrane entities receive their funding from different sources but 
agree to follow the policies and practices of the Cochrane Col-
laboration. 
The Cochrane Collaboration also employs two ombudsmen 
to help resolve areas of conflict that arise between people or 
entities, for which the usual process of involving their Centre 
Director has not been sufficient. 
The Cochrane Collaboration’s central functions are funded 
by royalties from its publishers, John Wiley and Sons Limited, 
which come from sales of subscriptions to the Cochrane Library 
containing the publications produced by the Cochrane Collabo-
ration. The individual entities of the Cochrane Collaboration are 
funded by a large variety of governmental, institutional, and pri-
vate funding sources and are bound by organization-wide policy 
limiting uses of funds from corporate sponsors. The Cochrane 
Collaboration’s sources of support can be found online.20 
Fowle offered his thoughts on how well the Cochrane Col-
laboration model meets the EBTC’s needs. While the EBTC 
has methodological and informational components like the Co-
chrane Collaboration efforts, the audiences of the two entities 
are likely to be different in a few important aspects. The medical 
orientation of the Cochrane Collaboration is likely more acces-
sible to individuals than is toxicity test qualification, which is a 
central focus of the eBtC, given that individuals are directly 
engaged in health care issues but are not directly engaged in 
the types of decision making that occurs in industry and regu-
latory agencies. Additionally, the various health outcomes that 
the Cochrane Collaboration deals with are real and can be seen 
in patients by physicians daily, while toxicity outcomes in hu-
man populations are sometimes theoretical because of measures 
taken to avoid any adverse outcomes. Finally, the Cochrane 
Collaboration deals with human health issues only. 
Because toxicology deals with environmental health as well 
as human health, Fowle suggested that the eBtC may wish to 
adopt this two-prong focus so that it is able to address the envi-
ronmental health mandates of US agencies such as ePA, the Na-
tional Marine Fisheries Service, the National Wildlife Service, 
the United States Geological Service, and corresponding state 
entities that are responsible for assessing risks to wildlife and 
ecological systems. 
Fowle raised points to consider for a future discussion about 
the formation, governance, and work processes of the EBTC. 
The EBTC’s success will depend in large part on the enthusiasm 
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The collaboration translates Cochrane reviews into other lan-
guages. 
2. Values. The Cochrane’s values are the foundation for what 
the organization does. They explain how the organization 
achieves its mission. The organization’s values include col-
laborating, avoiding duplication, minimizing bias, keeping 
up-to-date, ensuring relevance, and ensuring access. 
3. Business plan. The Cochrane Collaboration exists for peo-
ple who need the evidence – healthcare providers, decision-
makers, consumers, and researchers. 
4. Funding plan. The initial funding for Cochrane was by 
government agencies, especially those in the U.K. The or-
ganization became a nonprofit in 1996. Royalties from the 
Cochrane library are used for Collaboration-wide endeavors 
and to support annual meeting costs. Other than that, each 
entity is required to obtain its own funding.
5. Bylaws. Cochrane developed a policy manual that is avail-
able online and updated as needed.
The first thing the Cochrane Collaboration did was to hold an 
organizational meeting. It included 70 people from nine coun-
tries. The organization now has 28,000 people in more than 100 
countries, Scherer said. 
The Cochrane Collaboration steering group’s first meeting 
was in 1994. Scherer said that the steering group focused on in-
corporating the organization and planning the bylaws, as well as 
creating the software and discussing how to create a handbook 
to describe how to do the reviews. 
Soon after the organization was launched, it developed soft-
ware for conducting reviews. The organization also developed 
ARCHIE, an online repository for directories, reviews, and files 
shared by people within the Collaboration – similar to current 
cloud computing. The organization also has developed training 
materials and sponsors workshops to train people in conducting 
systematic reviews.
The Cochrane Library was created very soon after the for-
mation of the organization. It was initially published and made 
available online in 1996, and the online Cochrane journal is now 
published monthly. More recent activities include the review of 
diagnostic tests. 
Scherer concluded by exhorting the audience not to forget 
about what she called “the heart.” The operation of the Collabo-
ration has not always been a smooth ride. However, because 
everyone involved in the Collaboration shares the same vision 
– the heart – it has been possible to get through tough times. 
She said that while the EBTC needs to come up with bylaws, it 
is necessary to be flexible – what the EBTC chooses to do now 
may not be relevant in 15 years. Finally, she said that the trans-
parency and methodological rigor based on the empirical stud-
ies that underpin the Cochrane reviews are worth emulating. 
6.3  Invited discussant Rashid Shaikh
Rashid Shaikh of the Health Effects Institute (HEI) described 
a different organizational model for the EBTC, one that has 
proven successful in the environmental health and toxicology 
space. Rather than a detailed description of how to set up the 
organization, he focused on describing what the HEI is, how it 
is organized, and what it has achieved. 
The Cochrane Collaboration presents summary data in the 
form of “forest plots” to graphically depict the trials used in 
evaluating evidence on a particular topic and the level of con-
cordance between the trials, Scherer told attendees. The plot in-
cludes a horizontal line for each trial evaluated; the line’s length 
is based on its 95% confidence limits for the piece of evidence 
in question. A vertical line indicates the area of no difference, 
and a small diamond denotes the pooled result of the meta-anal-
ysis. The width of the diamond represents the confidence in the 
result, in terms of the meta-analysis. 
The Cochrane Collaboration’s “product” is The Cochrane Li-
brary, which Scherer said is widely considered to be the single 
best source for reliable information on the effects of healthcare. 
The Cochrane Library includes the Cochrane Database of Sys-
tematic Reviews. The database includes more than 4,500 full-
protocol reviews, as well as the published protocols themselves 
and methodology reviews. 
“We publish our protocols before we do the review; the pro-
tocols are also peer-reviewed by experts to make sure that our 
reviews will be relevant and important,” she said. The library 
includes a register of all of the clinical trials that have been iden-
tified via electronic and hand searching. 
the methodology reviews are systematic reviews of eBM/
HC research methods. The Cochrane methodology register is a 
collection of studies pertaining to research methodology. 
Scherer went on to describe a Cochrane review as a review of 
existing knowledge that uses explicit and scientific methods. All 
reviews are crafted at the outset to include a clear description of 
how they are going to be done, and all are designed to follow the 
rules the organization has created to ensure that all of the infor-
mation about the review process is transparent to all observers. 
Cochrane reviews include a clear description of the research 
question. To avoid duplication of effort, each review is regis-
tered before the protocol is written to ensure that the questions 
are relevant, important, and have not already been asked by 
someone else. Each review specifies the inclusion and exclu-
sion criteria for the randomized control trials that will serve as 
evidence. The review stipulates how the reviewers are going 
to identify this evidence, including which databases they will 
search, and whether any searching will be conducted manually. 
Reviewers define the search strategy they will use before they 
begin because that will be part of the publication. Reviewers 
specify the methods that they will use to assess the risk of bias, 
as well as the methods that will be used both to extract and to 
summarize the data. Studies are examined closely to see if they 
are similar enough to pool study results, i.e., whether there is 
clinical heterogeneity. Excessive clinical or statistical heteroge-
neity would preclude pooling study results.  
Scherer averred that the strength of Cochrane reviews is their 
rigorous methodology. They are collaborative efforts, and it is 
not unusual to have an international group of authors. 
Scherer also pointed out that reviews are performed independ-
ently of industry funding to avoid the perception of bias.
Scherer then provided details about the Cochrane Collabora-
tion on five points to aid in comparing it to EBT.
1. Mission. The Cochrane Collaboration is international, and it 
includes people in both developed and developing countries. 
Workshop report
Altex 30, 1/1394
– including the Research and Review Committees and special 
review panels – are appointed by the Board; for major appoint-
ments, such as chairs of committees, HeI sponsors may also 
consulted. The board, scientific committees, and staff all must 
undergo a conflict of interest disclosure process annually.
Shaikh emphasized that one of HEI’s key attributes is trans-
parency, which includes full public disclosure of all results, both 
positive and negative. HEI reports are detailed and comprehen-
sive, and the accompanying commentary provides both the con-
text and evaluation of the work. 
Shaikh stressed that HeI also is committed to allowing ac-
cess to data and other details to the entire scientific commu-
nity. Many HEI reports include extensive appendices that have 
original data or detailed data summaries. Following publication, 
access to data and methods are made available to other inves-
tigators. 
Other partners have joined HEI over the years, including 
other government agencies, the oil industry, and some chemical 
companies. Other organizations that support HEI’s work include 
the DOE, the FHWA, the American Petroleum Institute, CON-
CAWe, Hewlett Foundation, the Asian Development Bank, and 
others.  
 
6.4  Invited discussant Dennis Devlin
Dennis Devlin, ExxonMobil’s environmental health advisor, is 
also a board member and current president of the Health and 
Environmental Sciences Institute (HESI), whose mission is to 
bring scientists from academia, government, and industry to-
gether to address health and environmental issues. He was rep-
resenting HESI as a discussant.
Devlin complimented Fowle on his white paper, which he 
said served to lay down the foundation for furthering EBT. His 
goal, he explained, was to discuss practical considerations re-
lated to putting together a nonprofit organization and to respond 
to the questions that Fowle suggested he address. 
Devlin felt that the mission and vision were key statements 
for defining an organization, ensuring long-term commitment, 
and reaching out to potential funders. He pointed out that a 
mission should succinctly describe why the organization exists 
and that the vision should describe the organization’s aspira-
tions for what it will achieve. For both a mission and vision, 
Devlin stressed the importance of being precise and transparent 
so people have no doubt about why the organization exists. In 
considering the draft eBtC mission statement, he opined that it 
read more like a mixture of a mission statement, a vision, and 
work processes. All of these are very important, but each sepa-
rate statement has a concrete purpose. 
Devlin proposed a few mission statements for the eBtC for 
attendees to consider, such as “to add value to 21st century toxi-
cology by speeding the adoption of the best methods for next-
generation safety assessment testing.” Next, Devlin proposed 
a vision statement for the organization: “Enhanced decision-
making for safety assessments based on the development, as-
sessment, and adoption of evidence-based methods and testing 
strategies.”
Devlin said that it was important for a science-oriented non-
profit organization to divide its governance and procedural is-
He stressed that establishing organizations as independent 
and impartial is critical to establishing credibility with both the 
stakeholders and the larger public. Independence and impartial-
ity also are intertwined with the other key issues of funding and 
governing structure. Shaikh emphasized that communication 
with the scientific community, the public, and decision makers, 
is also very important. 
Shaikh explained that HeI was formed in 1980 in the context 
of the Clean Air Act’s section §202(a)(4), which required auto-
makers to test the health effects of automotive emissions. At that 
time, the science on which decisions about air quality standards 
were based was highly contentious. Industry leaders and EPA 
officials were motivated to find a better way to produce science 
that all parties would find trustworthy. 
According to Shaikh, HEI is structured to maintain credibil-
ity and transparency on scientific issues pertinent to regulatory 
questions in the air pollution and health areas, which are often 
controversial. The organization strives to maintain a balance of 
government and industry funding. While the EPA and the motor 
vehicle industry provide a significant portion of HEI support, oth-
er government and private groups also support the organization. 
HEI has an independent board of directors and two scientific 
committees, Shaikh explained. The people serving in these ca-
pacities are respected senior leaders, recognized for integrity 
and scientific accomplishments, and are not employed by the 
auto industry or other government agencies associated with 
Clean Air Act regulations. He added that HEI does not take 
policy positions and that its work is solely focused on scientific 
research and evaluation. 
HEI’s mission is to provide independent, impartial, high-
quality and timely science on the health effects of air pollution. 
The outlines of HEI’s work are planned in advance through a 
comprehensive process: HeI consults with ePA and automotive 
industry sponsors, as well as other agencies, including the Na-
tional Institute of Environmental Health Sciences (NIEHS), the 
Department of Energy (DOE), and the Federal Highway Admin-
istration (FHWA). The scientific community and a wide variety 
of NGOs and other groups are also invited to offer suggestions. 
Through this process, HEI develops a blueprint for five years of 
work, which is termed their Strategic Plan.
Once the Plan has been completed and the outlines of the re-
search agenda have been set, the research to implement it be-
gins. HEI develops requests for applications and funds research 
through a competitive process. Research is overseen by HEI 
staff and the Research Committee. At the end of the research 
phase, each investigator prepares a report, which describes the 
work in far greater detail than scientific papers. Next, the Re-
view Committee, which has no role in selection or oversight of 
the research, conducts a peer-review of the report and prepares 
a commentary. HEI publishes the report and commentary on its 
website and in print. 
From time to time, HEI also prepares broad reviews of a field 
of science, for example, health effects of exposure to traffic-
related air pollution or health effects of ultrafine particles. 
HEI selects its board of directors after consultation with 
HEI’s core sponsors, including the EPA Administrator and a ma-
jority of the motor vehicle industry. The scientific committees 
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pare, maintain, and update reviews may make sense, for exam-
ple. The question is: Will the EBTC provide the information 
for free? (The Cochrane reviews are available via subscription.) 
Review groups should likely be formed around certain techni-
cal areas, beginning with something that is achievable, perhaps 
developmental toxicity. 
Devlin said he also felt that methods groups would be useful 
to improve methods to capture and use evidence, conduct, and 
apply reviews. Some kind of a users’ network would be useful, 
he noted.
 The board and the scientific steering group, as well as the 
funders, will decide what structures/entities should be estab-
lished. The board also will determine who the leaders are. In 
the US, nonprofit organizations require boards of trustees to be 
responsible for the oversight of the entire enterprise, including 
the chair and vice chair, secretary, and treasurer. 
The role of the executive director is critical, Devlin said. That 
person must focus on short- and long-term strategies, staffing, 
and many other important issues. 
the steering committee is going to focus on the technical con-
tent. It could be a subcommittee of the board, he pointed out. 
Membership for the board and steering committee could begin 
with the existing steering committee. Key questions to consider 
include whether funders require representation and whether 
there is a future role for official members/participants. He said 
he doubts whether EBTC needs all positions of the Cochrane 
Collaboration. Fit for purpose is what is needed, he said. 
Devlin thought that one area where the Cochrane Collabo-
ration may not be a good starting point is in developing the 
EBTC’s bylaws, partly because Cochrane is essentially a UK-
based organization. It would probably be better to work with a 
group more familiar with US law. Devlin concluded by showing 
the bylaws for HESI, which he said were quite a bit simpler than 
the Cochrane Collaboration’s bylaws. 
6.5  Invited discussant Andrew Rowan
The final discussant was Andrew Rowan, who is the CEO of the 
nonprofit Humane Society International, as well as a member of 
the Human Toxicology Project Consortium, which seeks to ac-
celerate pathway-based approaches to toxicology.21 
Rowan welcomed the attention to good management prac-
tices, arguing that not nearly enough attention is paid to such 
issues in the nonprofit world. 
Rowan counseled that the name “evidence-based toxicology” 
may be off-putting to some, given that “all of us – I would hope 
– are using evidence.” 
He questioned the frequent calls for impartial people in en-
deavors such as the EBTC. “There’s not an individual in this 
room who is impartial, in the sense of being completely blank 
without opinions, biases, or prejudices,” he contended. “I would 
much rather that we have partial people who are identified with 
particular positions arguing vigorously on behalf of their posi-
tions,” he said. 
Part of the impetus for the Cochrane Collaboration was that 
peer-review was not doing what it should be doing, Rowan said. 
sues into two camps – administration and the scientific process 
of the output – and to consider these issues separately. Non-
profit organizations require a number of administrative tasks to 
be completed, including developing a business plan and a board 
of directors, which would be a group of experts separate from 
the scientific Steering Committee. It would not be appropriate 
to put the top-notch scientists on a board of directors dealing 
with budgets.
the administrative plan requires external expertise, including 
a facilitator, lawyers, finance, communication, and human re-
sources. Devlin felt that the plan proposed by Fowle represented 
a good starting point in incorporating Nonprofit Law & Govern-
ance For Dummies. 
Devlin noted that developing a strategic scientific plan will 
take time and a diverse group of dedicated stakeholders, but the 
effort is certainly worth it. One of the steps that such a group 
would take would be to confirm and adapt the mission and the 
vision and use them to develop the strategic plan.
to illustrate how strategic planning can work, Devlin ex-
plained how HESI does it. HESI’s scientific plan is always five 
years out. To meet that challenge, HESI has four strategic priori-
ties. For each priority, there are supporting objectives. Impor-
tantly, there is a background document that clearly articulates 
accountability. Devlin showed the group HESI’s strategic plan 
for 2011-2015 to illustrate how this kind of information can be 
presented concisely and clearly to keep everyone on the same 
page. 
Devlin remarked that the EBTC’s mission statement should 
be crafted in such a way that everything the organization does 
and/or could do can be evaluated against it. 
In response to the question of “what are the needs and expec-
tations of our stakeholders,” Devlin said that he didn’t know the 
funding mechanism and didn’t see relevant details in the docu-
ments. He asked whether the funders have special interests. For 
an organization like this, having short-term success is important 
both to maintain morale and to ensure funding, he said. He ad-
vised the eBtC to try for a success, even a small one, within 
3-4 years. 
Devlin suggested that the organization should provide tools 
to assess methods in the “increasingly diverse toxicology tool-
box,” as well as reviews identifying the most promising existing 
and emerging methods. The EBTC may maintain databases and 
an electronic library to provide access to guidance and assess-
ment documents. 
An important issue is how the eBtC is differentiated from 
other groups and that, in order to do this, one must consider who 
the “others” are. Devlin believed this particular endeavor has 
many “others” and therefore the EBTC needs to differentiate 
itself and then to actively decide if it will collaborate or com-
pete for both experts and dollars. The presumption is that EBTC 
will be collaborating, because working together and dividing 
the pieces can be a good way to produce useful results. 
In terms of structure, Devlin recommended simplifying the 
Cochrane Collaboration’s approach, which he thinks has merit. 




about how this will actually relate to and improve whatever our 
separate visions are of toxicology. 
She proposed that the next step might be to put out an open call 
for nominations for crisp proposals that might fit into two areas:
1. Applying EBT tools in evaluating a method. For example, 
all in vitro tests for estrogenic activity might be evaluated for 
evidence of disruption of estrogenic function in humans.
2. Looking through the toxicological literature on dioxin and 
see if one can do a systematic review examining the evidence 
associating exposures to dioxin with developmental toxi-
cology – or some other endpoint that one could succinctly 
phrase. 
Silbergeld said that she would be wary of joining an organiza-
tion aimed at promoting something like eBt without having 
a sense that this really is something that our field is ready to 
incorporate. She also argued for a broader vision beyond ad-
vancing in vitro methods. Think of Cochrane’s vision, which is 
to improve healthcare, she pointed out. She therefore suggested 
that although one component of the EBTC’s mission could be 
to advance new methods, restricting it to that would limit con-
sumer and public interest in and support for this activity.
John Fowle asked Roberta Scherer to say more about the 1993 
pilot project that led to the creation of the Cochrane Centers and 
how it served as a driver that gave the organization momentum. 
Scherer said that the initial development of the Oxford Database 
of Perinatal trials was a proof of concept that showed that evi-
dence-based medicine evaluations were possible. However, she 
also noted that a concerted effort to do systematic reviews was 
happening at the same time. “It was an intersection of a need 
and the methodology being there and developed at the same 
time,” she observed. The Oxford Database of Perinatal Trials 
showed that this intersection could result in something that was 
valuable, she said.
Fowle said that his research drove home the point that it takes 
a lot of work to set up an organization and, consequently, it is 
necessary to be fully committed to it and have clear objectives 
for it. To that end, he said it could make sense to develop a 
confidence-building pilot project first. Shaikh agreed, suggest-
ing that a pilot activity could be undertaken while some other 
things are being put into place. 
 Naidenko observed that it is important to consider who the 
organization’s users or clients will be. The Cochrane example 
seems like it was a lot easier to pull off. 
Fowle said that a pilot project could generate an “early win” 
and thereby help drive funding and support for EBT. He agreed 
with Naidenko that considering who the organization’s clients 
would be may also be helpful in this regard.
Terry Quill of the Quill Law Group, who was trained as a 
toxicologist, observed that the conference seemed to play out 
something like a roller coaster ride. He concluded that EBT for 
the 21st century is associated with two issues. The first is evi-
dentiary science and how toxicology should deal with that in the 
future with the idea that something different is needed. The sec-
ond issue is the new 21st century techniques and how the field 
is going to deal with them. “I’m afraid that what’s happening is 
that, depending on who is talking, there’s an emphasis on one 
side or the other.” 
Peer-reviewed papers are no doubt preferable to papers that 
have not gone through peer-review, but they are not necessarily 
great, he said. 
In the context of the need to objectively assemble evidence, 
Rowan argued that emotion is an important part of decision mak-
ing. He cited the work of Antonio Damasio, such as Descartes’ 
Error, in revealing how important emotion is in decision mak-
ing. Damasio observed that when emotion is eliminated via a 
frontal lobotomy, people’s ability to make decisions is impaired. 
Lobotomized people cannot distinguish between important and 
unimportant decisions, Rowan explained. 
“In fact, the human brain is a rather poor mechanism for de-
ciphering large sets of conflicting variables,” Rowan said. We 
tend to eliminate a whole lot of stuff because of emotional com-
mitments that have been built up over the years, and then we can 
make a decision between two or three options, he observed. 
People are also good at intuitive decision making. Efforts to 
program computers to be chess masters have revealed how com-
plicated intuitive decisions really are, he said. 
Rowan’s plea to the group was not to seek complete imparti-
ality by avoiding corporate funding. “Corporate funding can be 
very useful,” he observed. “It can bias results if you let it, but if 
you have NGO activists in the system, it probably won’t.” He 
agreed with his predecessors on the value of transparency. 
Rowan agreed with some researchers who have argued that 
most animal research is poorly designed. Much of it is not 
double-blind, for example, he said. There are interesting issues 
involved in what we accept as evidence and how much we will 
accept as evidence, Rowan continued. 
Rowan expressed his belief that mission and vision state-
ments should be as concise as possible, as well as memorable. 
He then proposed for the EBTC mission statement, “to enhance 
trust in and integrity of toxicology and regulatory science” and 
for the vision statement: “to create a safer world for humans, 
animals, and the environment.” He posited that everyone in the 
room could agree that these were worthy goals.
Rowan argued against following the Cochrane Collabora-
tion’s path into becoming a publishing company. “Having to 
pay a publishing company for access to these materials, to me, 
is not transparent,” he said. “I think transparency requires open 
access.” 
Funding issues are important, Rowan continued. He urged the 
EBTC to be completely transparent regarding where its money 
comes from and where it goes. Although he said that this infor-
mation is available for the Cochrane Collaboration in the U.K., 
he was unable to find funding information for its U.S. arm. 
Rowan concluded by reiterating his observations that corpo-
rate money might prove helpful to the eBtC and that transpar-
ency is likely to serve the organization well. 
6.6  Open discussion
Ellen Silbergeld opened the discussion by commenting that a 
good next step might be to try out some examples in an effort 
to find out how to operationalize the concepts that had been dis-
cussed during the workshop. She said that this could build confi-
dence and shape the way that the vision statement is formulated. 
There are still a lot more things that need to be thought through 
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We at Johns Hopkins are very much committed to eBt, Har-
tung stressed. His endowed chair is in the denomination of EBT 
because the Doerenkamp-Zbinden Foundation in Switzerland, 
which endowed the chair, and Johns Hopkins agreed that this 
is a worthwhile effort. This is a continuation of the work that 
Hartung began at ECVAM.
That said, Hartung stressed that his institution’s commitment 
to EBT does not imply any ownership. “We don’t want to own the 
process, but instead to help it along, and we will be very happy if 
the process is taken further by others in the future,” he explained. 
EBT is not intended to be focused on alternative methods under 
a new name, he stated. Nor is it toxicology of the 21st century 
under a new name. It is meant to be something that adds a com-
ponent that is lacking in the field of toxicology, he said. It is a 
driving force towards guiding the way we handle information. It 
is not meant to produce new methods or to replace methods. It is 
meant as a process of bringing a certain type of thinking into our 
debates, which might be beneficial for all of us. 
Johns Hopkins’ EBT effort has continuing support from the 
Doerenkamp-Zbinden Foundation. This will enable it to provide 
very limited funding for carrying out workshops and dedicated 
small studies via organizations such as the Transatlantic Think 
Tank for Toxicology (t4). We are trying to provide compensa-
tion to individuals who want to conduct some type of systematic 
reviews. At present, the amount available for agreed, dedicated 
studies is € 10,000 each, which at the time of the workshop 
equated to between $ 13,000 and $ 14,000. Hartung said he 
hoped that the funding would help motivate people to initiate 
reviews and to compensate them for some of their costs. It will 
be linked to the opportunity to publish the review in ALTEX, 
which currently has an impact factor of 4.4, he said.
Hartung said he is discussing with his Center’s management 
the possibility of providing additional funding for encouraging 
the production of systematic reviews in the future. He said he had 
between $ 200,000 and $ 250,000 per year to sponsor research, 
and some of this might become available for systematic reviews.
Hartung said that a philanthropic donor has provided funding 
to establish and maintain the EBTC secretariat; this represents 
the most important source of funding via an agreement that is 
valid for five years. The funding supports Martin Stephens as 
the organization’s director, as well as a support person. It also 
includes funds for supporting steering group travel. Taken to-
gether, this suggests that the eBtC has some foundation for fu-
ture achievements. The next steps are to move ahead to discuss 
the organization’s structure, as well as potential pilot projects. 
He concluded by saying that the day’s discussions had been 
very helpful.
7  Discussion
7.1  The nature and scope of evidence-based 
approaches
the workshop served to clarify the nature and scope of evidence-
based approaches in general and EBT in particular among the 
participants. Some participants equated EBT with test methods 
validation, rather than as a set of approaches and tools to as-
Quill asked the participants if what the group wanted to do 
was to use weight of evidence in toxicology in ways it has not 
yet been applied. “If that’s what this group wants to do, there’s 
certainly a need for it,” he commented.
Quill observed that the new techniques now available to toxi-
cologists have many potential benefits, including saving money 
and time, as well as facilitating better health decisions. “On the 
other hand, we could spend more money if we have higher false 
positive rates,” he said. To him, this raised the question of what 
the group was going to do to see that the techniques are properly 
validated, relevant, and useful. 
Validation is going to be key, Quill continued. “I’m afraid of 
the possibility that we may just throw these assays out there and 
people will misuse them and misuse the data,” he said. If that 
happens, he posits that the field will be in a worse position than 
it is now.
Rowan commented that the key difference between in vivo-
based toxicology and in vitro systems is the volume of data the lat-
ter produces. Within a year, we could test all the 30,000 REACH 
chemicals for which there is currently very little data and produce 
some biological data with 200 different assays at 15 different con-
centrations. It’d cost about $ 1500/chemical,” he said. 
“What the data means is of course another issue,” Rowan 
continued. But he argued that the whole-animal assays conven-
tionally used in toxicology studies have never been validated, 
beyond the fact that they were being conducted on mammals 
and humans are mammals. 
According to Rowan, “[w]hat we’re doing currently is not go-
ing to get us very far very fast. Even if we have more questions, 
we’re not going to do more animal testing because the capacity 
isn’t there to do it. The answers also aren’t there from historical 
animal testing. Do you think $ 35 million for more BPA studies 
is going to produce a clearer outcome for BPA? I don’t. Proba-
bly what will happen is the corporations will slowly move away 
from it because it’s problematic.”
“It’s the volume of data that’s going to be the real driver of 
this, and the fact that we’ll have to interpret it as we go along,” 
Rowan summarized.
Richard Woychik of NIEHS felt that Silbergeld’s comments 
at the beginning of the open discussion were spot on. “It’s very 
important to define what EBT is and what it’s not. I hope that 
it’s not just in vitro studies. While at some point way down the 
road a series of in vitro studies may be predictive for toxicology, 
I don’t think we’re there yet. Nor do I think we’re going to be 
there in the near term.” 
Finally, Woychik said that he agreed with Silbergeld about the 
need for a crisply defined pilot study with some specific objec-
tives. 
Thomas Hartung thanked the people who contributed to the 
discussion for their thorough analysis and the excellent food for 
thought that it provided. “It’s most important that we keep the 
ball rolling now, because we are at a critical stage of forming 
something that is more than coming together.” 
The transparency aspect and financial considerations have 
been mentioned several times, he pointed out, and he said that 




7.2  General themes and recommendations
Several general themes and recommendations emerged from 
the workshop. First, the learning process during the workshop 
(see Section 7.1) led many participants to suggest a primary role 
for the EBTC in education and outreach on evidence-based ap-
proaches. 
A second over-arching theme was an obvious need to dem-
onstrate the value of evidence-based approaches to toxicology 
through case studies. Two of the three presentations featured as 
“case studies” in workshop Session 2 (Daland Juberg’s and Patri-
cia Harlow’s – see Keller et al., (2012) and Section 4.1, respec-
tively) have clear relevance to future work applying evidence-
based approaches to 21st century methods, but given the current 
embryonic state of EBT, these presentations were necessarily not 
demonstrations of how EBT had already been applied. However, 
Silbergeld’s presentation in Session 2 (Silbergeld and Scherer, 
2013) did summarize some evidence-based studies of the litera-
ture associating specific chemicals with certain adverse effects. 
Nonetheless, it was clear that the EBTC should organize a number 
of case studies to further demonstrate the value of evidence-based 
approaches to toxicology. Such early “wins” are likely to be im-
portant in securing stakeholder buy-in early in the process. 
 A third theme, recurring throughout the workshop, was the 
importance and challenge of transparency. Those carrying out 
eBt reviews should strive to adhere scrupulously to the eBM 
tenet of transparency. Yet EBT practitioners must cope with lim-
its to transparency in toxicology, such as those imposed by data 
confidentiality owing to corporate or regulatory policy. Any 
challenges posed by practices within toxicology would be in ad-
dition to those plaguing other fields, such as the tendency not to 
publish “no-effect” results (publication bias). 
Fourth, the workshop repeatedly highlighted the fundamental 
distinction between advocacy and analysis in the work of an 
organization promoting evidence-based approaches. The Co-
chrane Collaboration confines its work in EBM/HC to analysis, 
leaving advocacy to others who may decide to take up the re-
sults of Cochrane assessments and use them to promote changes 
in healthcare policy. This issue echoes the distinction in toxicol-
ogy between a test method’s assessment versus its regulatory 
acceptance, with the idea that eBt could address the former 
but regulators would make the judgment regarding acceptance. 
Workshop participants seemed comfortable to have the EBTC 
carry on the assessments-not-advocacy tradition as evidence-
based approaches are translated from medicine to toxicology. 
Finally, the workshop raised the important issue of who would 
be interested in the output of the EBTC, i.e., who would be the 
EBTC’s “customers.” The main end users of EBT reviews and 
guidance will be diverse, including:
– Scientists interested in carrying out evidence-based reviews, 
appraising the quality of published studies that they read, de-
signing their own studies to high standards, and writing up 
their own studies such that other scientists can better under-
stand and replicate the details.
– Decision-makers in regulatory agencies responsible for ap-
proval of new chemicals or re-evaluation of existing chemi-
cals, approval of new test methods, or the formulation of new 
testing programs
sess the evidence on any well-framed question in toxicology, 
only inter alia including questions regarding test method per-
formance. By the close of the workshop, participants confirmed 
that they better understood evidence-based approaches and the 
applicability of EBT. Participants also grasped the distinction 
between EBM/EBT’s distillation of the evidence and any policy 
decisions that others might draw from the evidence. 
This greater understanding of evidence-based approaches was 
largely a consequence of the presentations by Ellen Silbergeld 
(Silbergeld and Scherer, 2013) and Roberta Scherer (Section 
6.2), as well as their comments and Thomas Hartung’s com-
ments during the open discussions. The nature and components 
of a systematic review became clear. In addition, the following 
points were emphasized:
– Any policy-related decisions informed by systematic reviews 
are based not only on the evidence, but also on professional 
expertise and – in the case of EBM/HC – patients’ values.
– An organization’s values are an important part of its iden-
tity, and the resulting shared vision can carry an organization 
through difficult times.
– Taking industry funding for particular reviews could be per-
ceived as a source of bias.
In addition to a general orientation to evidence-based methods in 
medicine/health care and toxicology, Ellen Silbergeld mentioned 
examples of some of the few systematic reviews that had been 
conducted in toxicology, an approach that she and her colleagues 
have pioneered. These case studies examined the effects of lead 
and arsenic on human health and illustrated the use of forest plots 
(Navas-Acien et al., 2006, 2007). These were examples of the ap-
plication of evidence-based methods to hazard assessment. The 
written version of Silbergeld’s presentation, co-authored with 
Roberta Scherer (Silbergeld and Scherer, 2013), takes a some-
what more conceptual approach to the subject, providing a prac-
titioners’ view of the nature and importance of evidence-based 
approaches in medicine/health care, as well as the potential and 
the challenge of translating these approaches to toxicology.
The commentary by Kim Boekelheide – who is by training 
a physician familiar with EBM/HC – noted important differ-
ences between clinical medicine and toxicology, including the 
diverse experimental approaches in toxicology, which would 
make evidence synthesis more challenging (Section 4.2). He 
raised the important question of the extent to which eBt ap-
proaches might be able to prospectively guide new studies in 
a field, in addition to providing retrospective analyses of past 
studies. Others noted that once an EBT assessment has been 
completed, it also can provide feedback and inform how new 
data is generated, the types of studies that are conducted, and 
how studies are written up for publication. This feedback loop 
can help reduce the elements of bias and increase study quality 
in the discipline as a whole. 
George Woodall of US EPA’s National Center for Environ-
mental Assessment noted that many of the recommendations 
made during the workshop are also made in the NRC’s recent 
review of the IRIS program’s assessment of formaldehyde 
(NRC, 2011). He noted that those considerations are being inte-
grated into the IRIS program, which was encouraging to eBtC 
members. 
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Regardless of the validation approach taken, respondent ed 
Carney agreed with Judson that validating high-throughput as-
says for the purpose of prioritizing chemicals for more defini-
tive testing is a good place to start assessing their performance. 
Similarly, assays with a well understood connection to adverse 
outcomes, such as estrogen receptor binding, are good candi-
dates to carry forward. Moreover, he noted the unexplored chal-
lenge of validating groups of complementary assays, rather than 
single assays (Section 3.2). 
In the workshop presentation by Grace Patlewicz and the 
accompanying commentary by Patlewicz, Richard Becker, and 
Ted Simon, these commentators, like Judson et al., mention 
the possibility of carrying out a new generation of perform-
ance evaluations using evidence-based approaches (Section 
3.3). They argue, however, for a somewhat different evalua-
tion framework adapted from the Institute of Medicine report 
on biomarkers, which emphasizes analytical validation, quali-
fication, and utilization. Their preference for an approach that 
involves qualification echoes Patricia Harlow’s description 
of the U.S. FDA’s biomarker qualification program (Section 
4.1).
While the speakers in Session 1 alluded to evidence-based 
approaches being applied to the validation of high-throughput 
assays, the ensuing open discussion began to sketch what that 
process might look like in practice (Section 3.4). Its elements 
would include defining the criteria up front, listing the candidate 
chemicals, getting the planned procedure peer-reviewed prior 
to execution, making adjustments, and then carrying out the re-
vised procedure systematically. 
Transparency would be key throughout, so the process could 
not only be understood but also could be replicated by interested 
parties. Establishing performance standards for a validated assay 
or set of assays would facilitate the process of continuous im-
provement. 
The overall aim of the process would be to establish the fit-
ness for purpose of an assay by demonstrating its scientific ba-
sis. This is a type of relevance that is included, but not empha-
sized, in the current validation framework. It is a scientific or 
mechanistic relevance, whereas the current framework focuses 
on empiric relevance, i.e., correlation to results from reference 
tests (Hartung, 2010). 
The focus on test method validation as a suitable target for 
EBT also predominated in Session 3, “Setting Priorities for 
the Evidence-based Toxicology Collaboration.” In her presen-
tation, Fitzpatrick noted that the new toxicology calls for new 
approaches to validation, and that assessing fitness for purpose 
should be tailored to different purposes depending on the rel-
evant regulatory framework (see Section 5.1). Her presentation 
(prepared with Abigail Jacobs) parallels Judson’s presentation 
on mapping validation principles to the evaluation of high-
throughput assays (Judson et al., 2013). Fitzpatrick’s perspec-
tive was that of a regulator, addressing the importance of incor-
porating the emerging methods of 21st century toxicology into 
regulatory toxicology. She noted the inadequacy of the current 
validation paradigm to assess the performance of pathway-based 
assays and offered evidence-based approaches as a transparent 
and structured way to move forward.
– Decision makers in industry responsible for the safety of new 
chemicals being developed or existing chemicals already on 
the market
– Scientists in government, industry, and academia involved in 
developing and assessing new test methods
– Stakeholders in the NGO community interested in the in-
tersection of toxicology and public health, environmental 
health, and new test methods
Modernizing toxicological decision making and practices will 
be especially relevant to regulators in government and scientists 
in industry who are seeking to respond adequately to (i) regula-
tory drivers such as the ReACH chemicals program in the eU 
and the Endocrine Disruptor Screening Program in the US, (ii) 
societal demands to move away from the current animal-based 
testing methods, and (iii) the responsibility to test the enormous 
backlog of poorly tested chemicals already in commerce. In 
addition, technology developers have a financial stake in see-
ing that their innovations are assessed appropriately and imple-
mented into practice.
7.3  Toxicological and organizational priorities  
for the EBTC
Apart from the cross-cutting themes identified above, much of 
the workshop focused on more specific topics related to the pri-
orities that the EBTC might adopt. These discussions revolved 
primarily around the issues of validation and governance. 
7.3.1  Validation and evidence-based approaches
Much of the workshop program reflected the EBTC’s desire 
to apply evidence-based approaches to assessing the perform-
ance of new test methods, especially the pathway-based assays 
of 21st century toxicology. In this regard, the sessions provided 
food for thought rather than specific advice. 
In Session 1, Richard Judson presented a multi-authored 
white paper that extensively discusses how the current vali-
dation framework might be adapted to the assessment of 
high-throughput, pathway-based assays (Judson et al., 2013). 
Validation is an assessment of an assay’s (or group of assays’) 
reliability and relevance for a specific purpose. Judson focused 
on the purpose (or “context of use”) of prioritizing chemicals 
for later follow-up with more definitive, lower throughput test-
ing. In this context, he argued that assessing relevance will be 
a bigger challenge than assessing reliability, given the nature 
of robotic, high-throughput systems. The white paper stresses 
several themes that resonate with evidence-based approaches, 
including transparency, continuous improvement, and data 
quality. It also envisions the possibility of using evidence-based 
approaches as a means of expanding the validation toolbox and 
thereby offering an alternative to the current costly and time-
consuming validation framework, which is more suitable to 
lower throughput methods.
Respondent Doug Wolf argued that a test method’s through-
put should be key to determining whether its performance is 
assessed with the current validation approach or a more eBt-
focused approach, with lower throughput assays being assessed 




– Similarly much of the data on emerging test methods might 
be in databases rather than published studies, so this would 
require new approaches to assessment.
Judson suggested that the ePA eDSP might offer a good starting 
point for an EBT analysis of pathway-based testing. One could 
assess how well the proposed “EDSP21” assays can serve to 
prioritize chemicals for testing in the tier-1 battery. 
7.3.2  Governance and work processes
While workshop Sessions 1-3 primarily explored the nature 
and scope of eBt and the types of toxicological questions 
that the EBTC might address (especially the issue of assessing 
test method performance), Session 4 explored how the newly 
formed EBTC might organize itself and carry out its work to 
pursue its mission efficiently. 
In his presentation, John Fowle provided a comprehensive re-
view of the issues that the eBtC should consider as it contem-
plates establishing a formal organizational structure and work 
processes (see Section 6.1). He presented a detailed discussion 
of the Cochrane Collaboration, which could serve as a model for 
the EBTC to adopt and to adapt. Fowle’s more general advice 
included the following: that the eBtC should strive to appeal to 
hearts as well as minds, that it seek to achieve some short-term 
wins to demonstrate its potential, and that it take the time to get 
its governance and work processes right from the start (“going 
slow to go fast”). 
The invited discussants were complimentary of Fowle’s rec-
ommendations. There was general agreement on the issue of 
looking to the Cochrane Collaboration as a model to draw or-
ganizational and administrative guidance from, as appropriate. 
Roberta Scherer provided additional background information 
on the Cochrane Collaboration (Section 6.2), whereas Rashid 
Shaikh (Section 6.3) and Dennis Devlin (Section 6.4) discussed 
the Health effects Institute and Health and environmental Sci-
ences Institute, respectively, as additional organization models 
that the EBTC could learn from. The final discussant, Andrew 
Rowan, offered advice on a wide range of organizational issues 
based on his experience in non-profit management and journal 
editing (Section 6.5).
While addressing administrative issues may be tedious at 
times, they are of paramount importance to the future success 
of the EBTC. As Fowle pointed out, how well the EBTC ad-
dresses these issues could mean the difference between success 
and failure in winning the hearts and minds of the hundreds of 
volunteers that the eBtC is hoping to recruit to carry its impor-
tant work forward. He noted that these issues may not seem like 
priorities in the heady days of embarking on a new initiative, but 
their importance warrants early attention. 
Scherer’s presentation included historical remarks that pro-
vided a sense of how the Cochrane Collaboration grew and 
evolved over time. Drawing on this experience should be help-
ful to the eBtC as it grapples with its administrative priorities 
while evolving over time and seeking to strike the right balance 
between subject-matter priorities and administrative ones.
Among the many key points made in the governance session 
were the following:
– the importance of an organization’s mission and vision state-
the invited discussants and other commentators from Ses-
sion 3 agreed with Fitzpatrick and Jacobs on using evidence-
based approaches to assess the performance of pathway-based 
assays as one of the goals of the EBTC (Sections 5.2-5.5). 
Such assessments would be comparable to EBM’s assessments 
of diagnostic tests and could be viewed as providing a kind of 
quality assurance to the new toxicology’s emerging methods. 
In keeping with the tenets of evidence-based approaches, these 
assessments should be carried out in a transparent manner. 
They also should involve diverse stakeholders. Multi-stake-
holder assessments may be liable to reflect biases stemming 
from differences in values and experiences but, fortunately, 
evidence-based approaches are ideally suited to handle poten-
tial bias. 
Workshop Sessions 1 and 3 highlighted the importance of 
pathway-based testing and the need for new ways of assessing 
the performance of such testing, with a clear call for mecha-
nistic validation established through evidence-based means. 
Two of the three presentations in Session 2 explored biologi-
cal questions that will be central to mechanistic validation of 
pathway-based methods. Daland Juberg addressed the issue 
of distinguishing chemical effects that lead to adverse versus 
adaptive changes in pathway-based assays (Keller et al., 2012). 
this question is at the heart of the NRC vision of toxicology in 
the 21st century (NRC, 2007). Similarly, Patricia Harlow ad-
dressed the evaluation of proposed biomarkers of biological ef-
fects, in the context of the biomarker qualification program of 
the US FDA’s Center for Drug Evaluation and Research (see 
Section 4.1). Once qualified and publicized, such biomarkers 
can be pursued within their context of use as indicators of the 
biological process in question, e.g., nephrotoxicity in rats, to 
facilitate the drug development process. Assessing the perform-
ance of a proposed biomarker is comparable to making a diag-
nosis – how well does the biomarker in question diagnose or 
predict the purposed effect. In her presentation, Harlow did not 
go into the scientific details of the review of particular proposed 
biomarkers, but she mentioned that the diagnostic performance 
of urinary biomarkers for nephrotoxicity in rats was evaluated 
by comparison with currently used nephrotoxicity markers us-
ing receiver operating characteristic (ROC) curves – a tool com-
monly used in eBM/HC assessments in diagnosis and likely to 
feature prominently in the emerging eBt assessments of test 
method performance. 
The workshop also identified several other issues that will 
need to be addressed when grappling with the validation of as-
says (high throughput or otherwise), whether by means of EBT 
or not. These issues include the following:
– The proper focus of a validation exercise could be an indi-
vidual assay or a group of complementary assays. 
– The EBTC should not be perceived as biased in the outcome 
of validation exercises, such as by giving the impression of 
a hidden agenda in wanting to see animal-based methods re-
placed by in vitro methods. 
– The EBTC may face the potential challenge of seeking to re-
view the literature on the performance of emerging test meth-
ods that are so new that few studies have been published on 
their performance. 
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7.5  Concluding remarks
the eBtC will seek to foster a growing interest in the appli-
cation of evidence-based approaches in toxicology. The appli-
cation of these new approaches is expected to strengthen the 
scientific basis of decision making in toxicology and to improve 
the transparency of research results, decision making, and the 
reporting thereof. Better-structured publication of information 
will facilitate evidence appraisal and synthesis when perform-
ing systematic reviews. 
With respect to validation, adopting and adapting assessment 
methodologies from medical diagnostics to toxicological tests 
is expected to fertilize the development of highly relevant and 
targeted toxicological testing methods and strategies. The use 
of test methods based on human biology rather than animal/
rodent biology will bridge both the gap and the unquantifiable 
uncertainty of inter-species differences. It is expected that new 
technologies (biomarkers and -omics) can be more rapidly in-
troduced as standard methods as evidence-based approaches 
supplant the time-consuming and cumbersome validation pro-
cedures of today. In addition, frequent evidence-based reviews 
of methods will help identify strengths and weaknesses of meth-
ods in practice, providing guidance for future improvements 
and developments. 
Bringing new approaches to the assessment of test method 
performance will be particularly timely. As toxicology moves 
to pathway-based approaches (as exemplified by the NRC re-
port on Toxicity Testing in the 21st Century (NRC, 2007)), the 
field will need new tools for assessing test method perform-
ance, especially as the focus shifts from animal to human biol-
ogy. Similarly, as test methods are developed to assess effects 
at multiple levels of biological organization (e.g., organ on a 
chip), tools will be needed to synthesize such data in ways that 
are transparent, objective, and systematic. Ultimately, this ef-
fort will open up new approaches to hazard and risk assess-
ment with the ability to flexibly integrate new evidence or 
adapt to it.
A modernized toxicology allowing transparent, objective, and 
consistent decision making based on the best and latest avail-
able scientific evidence will increase confidence and trust of the 
stakeholders in government, industry, academia, as well as NGOs 
who have an interest in and are affected by these decisions.
Modernizing toxicological decision making and practices 
will be especially relevant to those government regulators and 
industry scientists who are striving to assess a backlog of inade-
quately tested chemicals, such as through the ReACH program, 
as well as to scientists in government, industry, and academia 
who are seeking to implement pathway-based testing along the 
lines proposed in the 2007 NRC report cited above. REACH 
entails, among other components, a thorough assessment of 
toxicological dossiers on individual chemicals, which is best 
accomplished via an evidence-based approach. Pathway-based 
testing is developing too rapidly to be amenable to current vali-
dation approaches; evidence-based approaches can fill this void, 
especially where the reference standard shifts from high dose 
animal studies to human biology. 
ments, of periodic strategic planning, and of distinguishing 
the organization from similar groups;
– the challenges of administering an international organiza-
tion;
– the sensitivity over accepting corporate funding for specific 
projects;
– the importance of successful pilot projects to demonstrate 
value, inspire confidence, motivate staff, and attract mem-
bers and supporters;
– the need to clarify what EBT is and is not – If EBT applies 
to all methods in toxicology, not just in vitro or 21st century 
methods, and to all evidentiary-based questions in toxicol-
ogy, not just those around validation, then this should be 
stressed. 
Thomas Hartung noted that some funding is available to support 
the work of the EBTC as it moves forward on both sides of the 
Atlantic. In addition to supporting the secretariat, this funding 
could support workshops and small-scale studies.  
 
7.4  Next steps for the EBTC 
the US eBtC Steering Committee met one month after its 
January 2012 workshop to consider the presentations, discus-
sions, and recommendations from the workshop. The Steering 
Committee is establishing work groups to address the emerging 
toxicological, methodological, and organizational priorities for 
EBT, many of which were identified at the workshop. For exam-
ple, a methods work group will adapt the core eBM/HC-tools 
to the toxicology context. This group also will develop tools 
suitable for toxicological challenges that may not have close 
parallels in clinical medicine, such as evidence-based appraisal 
of data from heterogeneous types of studies (e.g., in vivo versus 
in vitro).
Specifically, the methods work group will generate guidance 
on topics such as information retrieval, data appraisal, evidence 
synthesis, and test method assessment. The resulting prototype 
guidance will need to be updated frequently as new insights are 
gained from their applications. 
In parallel, case study groups will explore how the guidance 
is to be used in practice and how the tools perform by address-
ing the evaluation of either a test method (or test strategy) or 
a health effect of a compound, or both scenarios. These stud-
ies are expected to demonstrate the feasibility of applying ev-
idence-based approaches in toxicology and to underscore their 
benefits as compared to standard practices. The components of 
these evidence-based approaches will be completely transpar-
ent, allowing ready reproduction and identification of any bias, 
e.g., the omission of data in a review. Ultimately, biases in toxi-
cology – a widespread but largely disregarded aspect in the field 
today – will be made amenable to assessment and exploration.
the eBtC also aims to further the conceptual development 
of EBT and raise awareness of its principles and approaches. 
The EBTC will evolve into an umbrella organization facilitat-
ing the application of evidence-based approaches to toxicology, 
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